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 mice develop hypertrophic lymph nodes, atherosclerosis and exhibit 
impaired immunity against pathogens. Hence, given the importance of lymph 
nodes in host immunity, we investigated these hypertrophic lymph nodes and 
understand how it contributes to impaired immunity in the mice.  
Our results demonstrated that the development and presence of hypertrophic 
lymph nodes in 22-28 weeks old apoE
-/-
 mice was associated with 
hypercholesterolemia and the progression of atherosclerosis. Hypertrophic lymph 
nodes displayed a significant increase over WT in lymph node cellularity, T and B 
cells. Both CD4 and CD8 T cells were also increased in hypertrophic lymph 
nodes but there was no bias towards either T cell subset, and no difference in CD4 
and CD8 T cell activation as compared to WT. In addition, immunofluorescence 
microscopy demonstrated that hypertrophic lymph nodes also did not exhibit 
disruptions in the general organization of the lymph node microenvironment. 
Mechanistic studies demonstrated that hypertrophic lymph nodes were not 
mediated by increased lymphocyte proliferation in the lymph node nor increased 
lymphocyte entry into the organ. Hypertrophic lymph nodes were mediated in part 
by impaired lymphocyte egress from the lymph node, and impaired egress was 
supported by the lymph node microenvironment alone. The lymph node 
microenvironment likely supports impaired lymphocyte egress through reduced 
S1P levels in the efferent lymph and lymph nodes, changes in the S1P 
concentration gradient between the efferent lymph as well as blood, increased 
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CCL21 retention signals, disrupted fluid flow in efferent as well as lymph node 
lymphatic vessels in the lymph node and dysfunctional lymphatic vessels. 
Finally, the treatment of hypercholesterolemia in apoE
-/-
 mice with the cholesterol 
lowering drug Ezetimibe ameliorated lymph node hypertrophy. The lymph nodes 
of Ezetimibe treated apoE
-/-
 mice demonstrated a significant reduction in lymph 
node cellularity, T and B cell counts as compared to non-treated apoE
-/-
 mice. 
This reduction in lymph node cellularity and T cells was mediated by a general 
restoration of T cell and total cellular egress but not B cell egress. Therefore, the 
reduction in B cell counts likely occurred by another mechanism(s). In addition, 
egress restoration occurred at least through a restoration of the lymph node 
microenvironment; lymph nodes of Ezetimibe treated apoE
-/-
 mice displayed a 
reduction in the size of the lymphatic vessel network as well as decreased vessel 
dilation. Hence, the reversal of lymphatic vessel abnormalities was sufficient to 
restore cellular egress. 
In conclusion, hypertrophic lymph nodes likely contribute to impaired immunity 
in apoE
-/-
 mice via the impaired egress of lymphocytes. Our results also support 
current models of lymphocyte egress from the lymph node, and suggest the 
suitability of apoE
-/-
 mice as an animal model to study the relationship between 
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1.1 The lymph node – an important organ for host immunity  
Lymph nodes are highly specialized organs that facilitate the induction of 
adaptive immune responses in the organism (Junt et al., 2008). Lymph nodes 
mediate this process by functioning as local ‘antigen repositories’ for recirculating 
naïve lymphocytes to find their cognate antigen (Gowans and Knight, 1964) and 
this ‘antigen repository’ is created through the strategic positioning of the lymph 
nodes at various locations in the body. Lymph nodes are positioned at the 
convergent points of afferent lymphatic vessels that drain antigen containing 
tissue fluid (lymph) from peripheral tissues into the lymph node (Junt et al., 2008; 
von Andrian and Mempel, 2003). Therefore, the lymph node receives antigens 
from the periphery which are subsequently internalized by lymph node resident 
antigen presenting cells (APCs) and presented to naïve T and B cells within the 
organ. In addition, the migration of antigen loaded dendritic cells (DCs) from 
peripheral tissues to the lymph node via the afferent lymphatic vessels further 
contributes to the antigen diversity of this ‘repository’.   
The facilitation of adaptive immune responses by the lymph nodes also 
extends beyond its function as an antigen ‘repository’. Lymph nodes also assist 
the induction of adaptive immune responses by concentrating naïve lymphocytes 
and APCs inside the organ (Junt et al., 2008; von Andrian and Mempel, 2003). 
This concentration of leukocytes inside the lymph node increases the probability 
of naïve lymphocytes encounters with APCs that bear their cognate antigen and 
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subsequent lymphocyte activation. This function may be seen during immune 
stimulus such as infection. During an infection, innate immunity mechanisms 
induce the proliferation of endothelial cells, subsequent expansion of the high 
endothelial venue (HEV) network and dilation of the lymph node feed arteriole 
(Soderberg et al., 2005; Webster et al., 2006). These actions increase the rate of 
lymphocyte entry into the lymph node and are further accompanied with a 
transient decrease in lymphocyte egress from the organ (Schwab and Cyster, 
2007). Hence, naïve T and B cells are concentrated inside the lymph node to 
encounter antigen-loaded APCs. 
When a naïve lymphocyte encounters its cognate antigen in the lymph node, it 
must decide whether to undergo differentiation into an effector cell or become 
tolerant in the case of reactivity towards self-antigens (von Andrian and Mempel, 
2003). For example, a naïve CD4 T cell can differentiate into a TH1 or TH2 
effector CD4 T cell in the event of appropriate co-stimulation or become anergic 
if the CD4 T cell recognizes a self-antigen. The lymph node plays a crucial role in 
this process by collecting the prerequisite information required for the lymphocyte 
to make its decision (Scheinecker et al., 2002). Thus, lymph nodes are also 
involved in the modulation of adaptive immune responses. 
Therefore, lymph nodes are vital organs that play a crucial role in host 
immunity through their roles in facilitating the induction as well as modulation of 





1.2 General organization of the lymph node microenvironment  
Lymph nodes can be distinguished histologically into the cortex, medulla, and 
the subcapsular sinus (a lymph-filled fibrous capsule that envelopes the entire 
lymph node).  
 
Figure 1.1 Schematic diagram of lymph node microenvironment (adapted from von Andrian 
and Mempel, 2003). (a) The main routes of lymph flow into and within lymph nodes are 
indicated by the arrows. (b) Magnified view of a paracortical cord demarcated in (a).  
 
The cortex occupies the outer region of the lymph node and can be further 
divided into 2 sub-regions, the B cell follicles and the paracortex. B cells 
congregate within the lymph node at the B cell follicles and these follicles lie 
below the subcapsular sinus of the lymph node. In addition, the B cell follicles are 
also the sites of germinal centre formation after immune stimulus. The paracortex 
is the lymph node region that contains the T cell zone, the location where naïve T 
and B cells enter the lymph nodes through HEVs (Marchesi and Gowans, 1964), 
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and the area where naïve T cells interact with antigen-presenting DCs (Mondino 
et al., 1996).  
Paracortical cords are also present within the paracortex, and these cords 
originate between or below the B cell follicles and extend into the medulla where 
they merge with the medullary cords (Kelly, 1975). Each paracortical cord is 
bordered by lymph filled trabecular sinuses and a HEV lies in the centre of every 
cord. The HEV is surrounded by concentric layers of fibroblastic reticular cells 
(FRCs) which form a FRC conduit to the subcapsular sinus and enclose corridors 
along which lymphocytes are believed to travel (Gretz et al., 1997). Finally, a 
narrow space called the perivenular channel exists between the basement 
membrane of the HEV and FRC layers. The arrangement and location of these 
structures are shown in Figure 1.1. 
The medulla occupies the inner region of the lymph node and it contains an 
intricate network of medullary sinuses that surround the medullary cords. The 
medulla is the site of lymphocyte exit from the lymph node but its function 
remains poorly understood. 
Finally, lymph and its components are transported towards the lymph node via 
afferent lymphatic vessels and enter the organ at the subcapsular sinus. Within the 
subcapsular sinus, lymph is transported in 3 different directions; lymph drains into 
the trabecular sinus and travels toward medullary sinuses, through FRC conduits 
into the perivenular channel near HEVs, or through a marginal reticular cell 
conduit to the B cell follicles in the cortex (Mueller and Germain, 2009). 
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1.3 Stromal cells of the lymph node  
1.3.1 Lymphatic endothelial cells 
Lymphatic endothelial cells (LECs) form the lymphatic vessels of lymph 
nodes which in turn, comprise part of the lymphatic vasculature of the organism. 
The primary role of the lymphatic vasculature is to collect extravasated fluid as 
well as macromolecules from tissues and return them to the blood circulation at 
the subclavian veins. This “blood-lymph loop” is essential for fluid homeostasis 
in the organism and disruption of the loop can lead to the development of 
lymphedema (Karpanen and Alitalo, 2008). Beyond fluid homeostasis, lymphatic 
vessels are also involved in lipid transport; dietary lipids are transported within 
lymphatic vessels from the gut to the liver (Karpanen and Alitalo, 2008; Schulte-
Merker et al., 2011).  
Finally, the lymphatic vessels are also involved in the host immune response 
against pathogens and disease. First of all, lymphatic vessels transport tissue fluid 
from the peripheral tissues to the lymph node in the form of lymph; this drainage 
route transports antigens from pathogens present in peripheral tissues to the 
lymph node for subsequent internalization by lymph node resident antigen 
presenting cells and presentation to naive lymphocyte that enter the lymph nodes 
(von Andrian and Mempel, 2003).  
Lymphatic vessels also contribute to host immunity by serving as a ‘dedicated 
highway’ for leukocyte migration into and out of the lymph nodes. Antigen laden 
DCs from peripheral tissues migrate to the lymph node via afferent lymphatic 
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vessels for antigen presentation to naive lymphocytes within the organ (Maby-El 
Hajjami and Petrova, 2008), while activated or naïve lymphocytes leave the 
lymph nodes via efferent lymphatic vessels to enter a downstream lymph node or 
return to the blood circulation. Hence, defects in lymphatic vessel function will 
exert a systemic impact on the organism. 
 
1.3.2 Blood endothelial cells   
The majority of blood endothelial cells in the lymph node consist of HEVs, 
which are specialized postcapillary vascular sites that function as principal sites of 
lymphocyte entry into the lymph node from the blood. HEVs are unique from 
other vascular endothelium in the organism by virtue of their ability to recruit 
large number of lymphocytes from the blood, and the possession of a unique 
vascular address that is not found in other microvascular beds (Girard and 
Springer, 1995). 
The HEV network of the lymph node is also involved in the immune response 
of the host. Innate immune mechanisms induce the proliferation of HEV 
endothelial cells and the dilation of the feed arteriole during an infection 
(Soderberg et al., 2005; Webster et al., 2006). These actions results in an increase 
in the rate of naïve lymphocyte flow to the lymph node as well as the expansion 
of the lymph node HEV network which subsequently result in an increased 
capacity of the lymph node to recruit lymphocytes from the blood. Thus, HEVs 




1.3.3 Fibroblastic reticular cells 
T cells and DCs of the lymph node T cell zone are embedded on a scaffold of 
mesenchyma stromal cells and these stromal cells are the FRCs (Katakai et al., 
2004a; Katakai et al., 2004b). In the T cell zone, FRCs reside on and envelope 
type 1 and 3 collagen rich reticular fibers, thereby forming an enclosed conduit 
structure that is separate from the lymph node parenchyma (Junt et al., 2008). 
These FRC conduits extend from the subcapsular sinus floor and crosses the T 
cell zone to form a continuous lumen with the HEV perivenular channel (Gretz et 
al., 1997). Therefore, lymph and its associated low molecular mass proteins 
(approximately <80 kDa) (Gretz et al., 2000) may be transported directly from the 
subcapsular sinus into the perivenular channel of HEV via these FRC conduits. 
Hence, FRCs serve as scaffold cells for the T cell zone and organize a passage for 
interstitial flow from the subcapsular sinus through the T cell zone to the HEVs. 
FRCs also perform other roles in the lymph node beyond their transport and 
structural functions. FRCs are involved in the regulation of T cell migration, 
survival and the induction of tolerance under homeostatic conditions. FRCs 
regulate T cell location in the lymph node through their production of CCL19 and 
the serine isoform of CCL21 (Luther et al., 2000) thereby defining the boundaries 
of the T cell zone. In addition, these chemokines also support T cell motility 
within the T cell zone (Forster et al., 2008; Sallusto et al., 1998). Finally, FRCs 
promote T cell survival through the delivery of homeostatic survival signals such 
as interleukin 7 (Link et al., 2007), and induce tolerance in T cells by the 
expression and presentation of autoimmune regulator and self-antigens (Jones et 
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al., 2007; Lee et al., 2007). Therefore, FRCs perform a wide diversity of roles in 
the lymph node which are essential for proper functioning of the organ. 
 
1.3.4 Follicular dendritic cells 
Follicular dendritic cells (FDCs) cluster in the centre of B cell follicles within 
the lymph node and form a dense network within which naïve B cells search for 
their cognate antigens as well as receive differentiation signals after activation 
(Mueller and Germain, 2009). The FDCs also express FC Receptors, complement 
receptors and complement components (C4) (Mueller and Germain, 2009); these 
surface components facilitate the capture of free antigens by FRCs and 
subsequent presentation of captured antigen to naïve B cells. Finally, FDCs also 
produce the chemokine CXCL13 whose interaction with its receptor CXCR5 on B 
cells directs these B cells into the B cell follicles during homeostatic conditions 
(Gunn et al., 1998a; Legler et al., 1998).   
 
1.4 Alterations in the lymph node microenvironment organization negatively 
affect host immunocompetence 
The organization of the lymph node microenvironment and its stromal cells 
has been shown in the above sections to be essential for the organ’s role in 
facilitating the induction of adaptive immune responses. Therefore, it follows that 
disruptions in lymph node organization or damaged stromal cells can negatively 
impact immunocompetance in the organism.  
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The negative impact of a disrupted lymph node microenvironment on host 
immunocompetence may be seen in the examples of infection with lymphocytic 
choriomeningitis virus (LCMV), and the increased vulnerability of germ-free 
mice to infections (Junt et al., 2008). Acute infection of mice with LCMV and the 
accompanying ‘cytokine storm’ results in the elimination of APCs as well as 
FRCs together with the loss of lymph node microenvironment organization, and 
these subsequently results in a transient loss of immunocompetance against 
secondary infections (Mueller et al., 2007; Odermatt et al., 1991; Scandella et al., 
2008). On the other hand, germ-free mice possessed a defective organization of 
the lymph node microenvironment (Macpherson and Harris, 2004) and 
demonstrated increased vulnerability to infections (Macpherson and Smith, 2006). 
This abnormalities in germ-free mice can be restored through colonization with 
commensal bacteria by placing a specific pathogen free mouse in a cage 
containing germ-free mice (Macpherson and Harris, 2004).   
Together, these 2 examples demonstrate the importance of proper organization 











1.5 Lymph node entry 
1.5.1 Entry of lymph, lymph-borne antigens and DCs into the lymph node 
Lymph as well as its antigen cargo are transported from peripheral tissues to 
the lymph node via afferent lymphatic vessels (von Andrian and Mempel, 2003) 
and subsequently enter the subcapsular sinus of the lymph node. Inside the 
subcapsular sinus, lymph and lymph-borne antigens are channeled through 3 
different routes – remain within the subcapsular sinus and flow towards the hilus, 
enter the trabecular sinus and flow across the lymph node parenchyma into the 
medullary sinuses and finally, enter the FRC conduits and flow towards the 
perivenular channel near the HEVs. Lymph borne antigens and molecules must be 
<80 kDa in molecular weight for entry and transport within the FRC conduits 
(Gretz et al., 2000). 
Like lymph fluid, DCs from peripheral tissues also travel to the lymph node 
via the afferent lymphatic vessels and enter the subcapsular sinus of the lymph 
node. Inside the subcapsular sinus, DCs migrate into the lymph node parenchymal 
compartment through the floor of the subcapsular sinus (Alvarez et al., 2008; 
Schumann et al., 2010) and subsequently travel towards the paracortex and other 
areas within the lymph node. This migration of DCs from peripheral tissues into 
the lymph node parenchyma is mediated by an increase in DC CCR7 surface 
expression (Gunn et al., 1999; Sallusto et al., 1998), and DC migration is further 
enhanced during inflammation through the expansion of the afferent lymphatic 
vessel network of the lymph nodes (Angeli et al., 2006). 
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1.5.2 Lymphocyte entry into the lymph node via HEVs 
Lymphocyte entry into lymph nodes via the HEV is a multistep adhesion 
cascade, and is the preferred route of entry for central memory T cells as well as 
naive T and B cells. This adhesion cascade can be divided into 4 steps: tethering 
and rolling of the lymphocyte along HEV endothelium, activation of lymphocyte 
surface integrin, firm adhesion onto HEV endothelium and finally transmigration 
of the lymphocyte across HEV endothelium into the lymph node (Okada et al., 




Figure 1.2 Summary of the adhesion cascade for lymphocyte entry into the lymph node via 
HEVs (adapted from von Andrian and Mempel, 2003). Lymphocyte entry into the lymph node 
via HEVs consist of 4 steps: tethering and rolling of lymphocyte on HEV endothelium, activation 
of surface integrin, firm adhesion of cells onto HEV endothelium and finally, transmigration 
across HEV endothelium into the lymph node.  
 
The entry process begins with the tethering of lymphocytes onto HEV 
endothelium (Step 1). This process is mediated by the interaction between CD62L 
(L-selectin) expressed on lymphocyte surfaces, and peripheral node addressin 
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(PNAD) which is expressed by HEV endothelial cells. The loose binding between 
CD62L and PNAD causes the lymphocyte to roll slowly along the endothelial 
wall due to the directional nature of blood flow within the HEV. 
The next step in the entry cascade is the activation of leukocyte function 
associated antigen 1 (LFA1) on the lymphocyte surface (Step 2). LFA1 activation 
on naïve and central memory T cells is mediated by the interaction between CC-
chemokine receptor 7 (CCR7) on the T cell surface (Campbell et al., 1998a; 
Campbell et al., 1998b; Gunn et al., 1998b) and CC-chemokine ligand 21 and 19 
(CCL21 and CCL19) of the HEV endothelial cells (Stein et al., 2000; Weninger et 
al., 2001). In B cells, LFA1 activation is mediated by the same CCR7 – 
CCL19/21 interaction, and an additional interaction between CXCR4 on the B 
cell surface and CXCL12 of HEV endothelial cells (Okada et al., 2002).  
The firm adhesion of rolling lymphocytes onto HEV endothelium comprises 
the 3
rd
 step (Step 3) of the entry cascade. This process is mediated by the 
interaction between activated LFA1 (from Step 2) on the lymphocyte surface and 
intercellular adhesion molecule 1 (ICAM-1) on HEV endothelium (Andrew et al., 
1998; Hamann et al., 1988; Warnock et al., 1998). The arrested lymphocytes 
finally cross the HEV endothelium (diapedesis) and enter the lymph node in the 
final step of the entry cascade (Step 4). The route of diapedesis by lymphocytes is 
uncertain but may involve cell migration into and out of individual HEV 
endothelial cells (Marchesi and Gowans, 1964), or migration though 
interendothelial cell junctions (Anderson and Anderson, 1976). In addition, it is 
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uncertain whether there are adhesion molecule and chemokine requirements for 
this process.   
Therefore, successful leukocyte entry into the lymph node via HEVs requires 
the expression of all receptors involved in the entry pathway; the absence of 1 or 
more receptors prevents lymph node entry through HEVs (Robert et al., 2003; 
Warnock et al., 1998; Weninger et al., 2001). This requirement is demonstrated in 
granulocyte recruitment into lymph nodes. Granulocytes express L-selectin and 
LFA1 but not CCR7; hence, LFA1 activation does not occur and these leukocytes 
are unable to enter the lymph nodes via HEVs under homeostatic conditions. 
 
1.5.3 Modulation of leukocyte entry into the lymph node by peripheral 
tissues  
Leukocyte entry into lymph nodes via HEVs may be influenced by peripheral 
tissues through the secretion of chemokines by these tissues into tissue fluid. This 
is due to the transport of these chemokines to the lymph node as part of lymph, 
chemokine entry into the FRC conduits of the lymph node and finally, 
presentation to rolling lymphocytes within the HEV lumen. This process is 
demonstrated in the example of skin inflammation (Figure 1.3), and chemokines 
that can be transported in this manner include the homeostatic chemokines 
CCL19, CCL21, CXCL12 (Baekkevold et al., 2001; Stein et al., 2000) and 




Figure 1.3 Peripheral tissue modulation of monocyte recruitment into the lymph node via 
HEVs (adapted from von Andrian and Mempel, 2003). (a) Inflammation in the skin results in 
the production and secretion of the inflammatory chemokine CCL2. (b) CCL2 is transported as 
part of lymph to the lymph node through the afferent lymphatic vessels. (c) Inside the lymph node, 
CCL2 in lymph is transported via the FRC conduit from the subcapsular sinus to the HEV.                      
(d) CCL2 is translocated onto the luminal surface of HEVs and activates CCR2 on rolling 
monocytes. This induces firm arrest of the monocyte and diapedesis (e) Another mechanism of 
lymph node entry via HEVs is the interaction between CXCR3 on the monocyte and CXCL9. 
However, the source of CXCL9 is unknown. 
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Inflammation in the skin induces the expression of CC-chemokine ligand 2 
(CCL2) and secretion into tissue fluid (Step a). CCL2 is then transported into the 
lymph node subcapsular sinus through the afferent lymphatic vessels (Step b). 
Inside the subcapsular sinus, CCL2 is channeled through the FRC conduits to the 
perivenular channel of the HEV (Step c) and finally, transcytosed across HEV 
endothelium into the HEV lumen where it interacts with its receptor, CCR2 on the 
surface of rolling monocytes. This interaction triggers the activation of monocyte 
integrin, and subsequent arrest of the monocyte onto HEV endothelium. The 
arrested monocyte then migrates across the HEV endothelium and enters the 
lymph node (Step d) (Palframan et al., 2001). Finally, CXCL9 – CXCR3 
interaction has been identified as another mechanism of monocyte recruitment 
into the draining lymph node during skin inflammation (Step e) (Janatpour et al., 
2001). However, the source of CXCL9 is still unknown. 
Therefore, peripheral tissues are able to modulate the composition of 
leukocytes in the lymph nodes through the process of chemokine secretion, and 
subsequent transport of these secreted chemokines to the HEV lumen for 
interaction with their specific receptor on leukocyte surfaces. In addition, this 
mechanism subsequently allows modulation of the adaptive immune response by 





1.5.4 DCs and functional afferent lymphatic vessels are critical for immune 
priming 
Lymphocyte homing into the lymph node is of no benefit to the organism 
unless these cells are presented with antigens by mature DCs (Banchereau et al., 
2000). This is because mature DCs present antigens to naïve lymphocytes more 
efficiently than other APCs and thus, exert a huge influence on immune reactivity 
or antigen tolerance (Sallusto and Lanzavecchia, 1999). In addition, DCs are also 
able to prime CD8 cytotoxic T cell responses against intracellular microbial 
infections (Jung et al., 2002), influence the differentiation of CD4 T cells into TH1 
or TH2 cells and in mesenteric lymph nodes as well as Peyer’s Patches, instruct T 
cells on where to locate their antigen in the periphery (Mora et al., 2003; Stagg et 
al., 2002). Finally, DCs achieve this immune priming of naïve lymphocytes by 
various means such as the upregulation of DC antigen presentation molecules, 
upregulation of T cell stimulation molecules and the generation of chemokines 
such as CCL3, CCL17, CCL22, CCL18, CCL19 and TXA2 which attracts 
lymphocytes to the mature DC (Adema et al., 1997; Godiska et al., 1997; 
Hieshima et al., 1997; Ngo et al., 1998; Sallusto et al., 1998).  
Equally important in the process of immune priming is the presence of 
functional afferent lymphatic vessels. This is because mature antigen-laden DCs 
enter the lymph node via these lymphatic vessels (Banchereau et al., 2000). 
Therefore, dysfunctional afferent lymphatic vessels can reduce the efficiency of 
immune priming by impeding the migration of mature DCs into the lymph node. 
In addition, because resident immature DCs in the lymph node also undergo 
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maturation through the uptake of lymph-borne antigens (Itano et al., 2003; von 
Andrian and Mempel, 2003); the presence of dysfunctional afferent lymphatic 
vessels can reduce antigen availability to these resident DCs and further 
contribute to inefficient immune priming within the lymph node. Finally, 
defective afferent lymphatic vessels may also reduce the ability of peripheral 
tissues to modulate leukocyte recruitment into the lymph node during 
inflammation and/or infection. 
 
1.6 Migration of newly recruited T and B cells within the lymph node   
Upon entry into the lymph node via HEVs, naïve T cells migrate away from 
HEV (Miller et al., 2003) and enter into the T cell zone through the interaction 
between CCR7 on T cell surfaces and CCL21 expressed by FRCs within the T 
cell zone. Inside the T cell zone, naïve T cells migrate rapidly in random 
directions so as to scan the zone for DCs that bear their cognate antigens (Miller 
et al., 2003). The T cells are kept within the boundaries of the T cell zone during 
their search for DCs through the interaction between CCL21 produced by FRCs 
and its receptor CCR7 which is expressed on naïve T cells.  
However, activated CD4 T cells are able to leave the T cell zone and migrate 
to the B cell follicles to provide B cell help. Activated CD4 T cells achieve this 
migration through a transient downregulation of CCR7 and upregulation of 
CXCR5 expression (Schaerli et al., 2000). The downregulation of CCR7 
expression reduces the activated CD4 T cell’s sensitivity towards FRC-produced 
CCL21 and thus, allows the cell to disengage from the T-cell zone while 
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upregulation of CXCR5 expression subsequently allows the activated CD4 T cells 
to respond to CXCL13 produced by FDCs of the B cell follicle. Therefore, the 
activated CD4 T cell homes to the B cell follicle through the interaction between 
CXCR5 on the T cell and CXCL13 produced by the FDCs. 
Naïve B cells also enter the lymph node through HEVs and they migrate to the 
B cell follicles through the interaction of CXCR5 on B cells and CXCL13 
produced by the FDCs within the B cell follicle (Gunn et al., 1998a; Legler et al., 
1998). Inside the follicle, the B cells also exhibit a random walk (Miller et al., 
2002) similar to naïve T cells within the T cell zone. In conclusion, T and B cell 
migration in the lymph node is heavily influenced by chemokine distribution; 
hence, any change in chemokine distribution is likely to disrupt lymph node 
organization.   
 
1.7 Egress of lymphocytes from the lymph node 
1.7.1 Sphingosine-1-phosphate as a central mediator of lymphocyte egress 
The interaction between sphingosine-1-phosphate (S1P) and its receptor 
sphingosine-1-phosphate receptor 1 (S1P1) on T and B cells is essential for 
lymphocyte egress from the lymph nodes. To date, this interaction between S1P1 
and its ligand S1P remains the only known major mechanism of lymphocyte 
egress from the lymph node.  
S1P interacts with 5 cellular receptors in vivo – S1P receptors 1-5 (S1P1, S1P2, 
S1P3, S1P4, S1P5) (Cyster and Schwab, 2012) and it serves 2 functions inside the 
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body; as an intercellular signaling molecule and an intracellular metabolic 
intermediate (Hannun et al., 2001; Saba and Hla, 2004; Spiegel and Milstien, 
2003). S1P is synthesized in vivo by the phosphorylation of sphingosine and 2 
enzymes are involved in the phosphorylation reaction; sphingosine kinase 1 and 2 
(Sphk1 and Sphk2). In addition, S1P can also be irreversibly degraded by the 
enzyme sphingosine-1-phosphate lyase (S1PL) to yield phosphoethanolamine and 
2-hexadecenal (Serra and Saba, 2010; Spiegel and Milstien, 2011).  
Finally, the S1P concentration in the extracellular environment is inversely 
proportional to T and B cell surface expression of S1P1 (Schwab and Cyster, 
2007). Thus, lymphocyte S1P1 surface expression is higher in a low S1P 
environment and lower in a high S1P environment.      
 
1.7.2 Lymphocyte egress from the lymph node follows a S1P concentration 
gradient 
Between the lymph node, lymph as well as plasma, S1P concentration is 
highest in plasma and is within the low micromolar range (Schwab and Cyster, 
2007). The high S1P concentration in plasma is likely to be mediated by 
erythrocytes whose S1P production accounts for a substantial portion of total 
plasma S1P (Pappu et al., 2007). Erythrocytes play a significant role in high 
plasma S1P concentration because they can produce S1P while also lacking 
enzymatic activity of all known S1PLs (Ito et al., 2007). Thus, S1P synthesis 
dominates over S1P degradation in plasma thereby resulting in a high S1P level.   
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In contrast to plasma, S1P concentration in lymph falls within the nanomolar 
range (Pappu et al., 2007; Schwab et al., 2005) and is approximately one sixth 
(1/6) the plasma S1P concentration. This reduced S1P concentration in lymph is 
due to the derivation of lymph from tissue fluid where the half-life of S1P is 
likely reduced. This reduction of S1P half-life in tissue fluid likely occurs through 
different mechanisms: i. lymph is obtained from the tissue fluid that bathes 
tissues, and ii. all 6 known S1PL are membrane associated and thus, are present 
on tissue surfaces where they are in contact with tissue fluid (Cyster and Schwab, 
2012). Therefore, the degradation of S1P in interstitial fluid of tissues as well as 
the derivation of lymph from tissue fluid thus prevents S1P transit from the 
plasma and results in a reduced S1P concentration within lymph.  
S1P concentration in the lymph node is the lowest among all 3 tissues 
(plasma, lymph and lymph node), and this low S1P concentration is maintained 
by a high S1PL activity within the lymph node. Like the plasma and lymph 
compartments, high S1PL activity also ensures that S1P in lymph does not transit 
into the lymph node. Therefore, a S1P concentration gradient exists between these 
3 tissues; S1P concentration is lowest in the lymph node, intermediate within 
lymph and highest inside plasma.  
Since T and B cells exit from the lymph node through efferent lymphatic 
vessels and re-enter the blood circulation, it is possible that the S1P concentration 
gradient between the plasma, lymph and lymph node is essential to egress. This 
requirement has been demonstrated in experimental studies where the inhibition 
of S1PL in lymph nodes resulted in an increase in lymph node S1P concentration 
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(Schwab et al., 2005), subsequent disruption of the S1P gradient and inhibition of 
T as well as B cell egress from the lymph node.  
In conclusion, T and B cell egress from the lymph node is mediated by the 
interaction between S1P in the environment as well as S1P1 on lymphocyte 
surfaces, and occurs along a S1P concentration gradient between the lymph nodes 
and blood. Disruption in the S1P concentration gradient results in a disruption in 
lymphocyte egress.  
 
1.7.3 Lymphocyte egress from the lymph node begins at the cortical sinus 
T and B cells exit the lymph node via the medullary sinuses and efferent 
lymphatic vessels (Cyster, 2005). However, an additional lymphatic route known 
as the cortical sinus is involved in the egress pathway prior to entering the 
medullary sinuses and efferent lymphatic vessels. Figure 1.4 illustrates the 
process of lymphocyte exit through the cortical sinus. 
When a T or B cell is ready to leave the lymph node, it makes contact with the 
lymph node cortical sinus and probes it (step 1) (Cyster and Schwab, 2012). The 
lymphocyte subsequently enters the cortical sinus if conditions are favorable 
(explained in Section 1.7.4) and this entry into the cortical sinus step requires 
S1P1 (step 2) (Pham et al., 2008). In addition, entry into the cortical sinus may not 
occur across the circumference of the vessel but rather, at certain hot spots or 




Figure 1.4 Multistep model of lymphocyte egress from the lymph nodes using T cells as an 
example (adapted from Cyster and Schwab, 2012). a. Exiting T cell makes contact with and 
probes the cortical sinus (step 1). The T cell enters the cortical sinus and this entry requires S1P1 
(S1PR1). Entry into the cortical sinus is also believed to occur at specific egress portals (step 2). 
Lymph flow inside the cortical sinus carries the cells to the medullary sinus, efferent lymphatic 
vessels and finally, out of the lymph node (step3). b. S1P1 is required for the entry of T cells into 




) cells can contact the cortical sinus but are 




) cells are both able to contact and enter the 
cortical sinus vessels 
 
Inside the cortical sinus, the lymphocyte detaches from the vessel wall, adopts 
a round shape, and becomes carried by fluid flow which transports the 
lymphocyte to the medullary sinuses and out of the lymph node (step 3) 
(Grigorova et al., 2010; Grigorova et al., 2009). The presence of lymph fluid flow 
within the cortical sinus and its role in transporting lymphocytes to the medulla 
suggest that disruptions in fluid flow within the lymphatic vessel may inhibit 
lymphocyte egress from the lymph node. 
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Finally, although current experimental data demonstrate that the initial stages 
of T and B cell exit occur at the cortical sinus, these data do not exclude the 
possibility that lymphocytes can also exit the lymph node via other routes such as 
direct entry into the medullary sinus or subcapsular space (Grigorova et al., 2009; 
Sinha et al., 2009; Wei et al., 2005).  
 
 1.7.4 Determinants of lymphocyte entry into cortical sinuses during lymph 
node egress   
T cell entry into the cortical sinus during lymph node egress is determined by 
the competition between T cell CCR7 and S1P1 surface expression (Pham et al., 
2008). When a T cell encounters a cortical sinus inside the lymph node, it extends 
membrane processes in 2 different directions; one membrane process projects into 
the cortical sinus while the other process projects into the T cell zone stroma 
(Cyster and Schwab, 2012). These membrane processes sample the 
microenvironment that surrounds it and the sampling comprise the lymphocyte’s 
decision making event regarding entry into the cortical sinus. Figure 1.5 illustrates 





Figure 1.5 T cell egress decision making at the cortical sinus (adapted from Cyster and 
Schwab, 2012). T cells are retained in the lymph node when CCR7 surface expression is higher 
such as during early activation of T cells, FTY720 treatment or recent recruitment into the lymph 
node from the blood. On the other hand, T cells leave the lymph node when S1P1 (S1PR1) surface 
expression is higher, and this occurs when a naïve T cells is activated and becomes an effector T 
cell.  
 
If T cell CCR7 surface expression is higher than S1P1 surface expression, the 
T cell is more responsive towards CCL21 produced by stromal cells of the T cell 
zone, and this overcomes the egress signal of S1P thereby leading to T cell 
retention within the lymph node. On the other hand, higher T cell S1P1 surface 
expression increases responsiveness towards S1P in the lymph of cortical sinuses 
and this overcomes the retention signal of CCL21. The T cell thus enters the 
cortical sinus and subsequently exits the lymph node.  
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Finally, although this egress decision process at the cortical sinus has only 
been shown for T cells, it is also possible that a similar egress decision might exist 
in B cells. 
 
1.7.5 Proper egress of lymphocytes from the lymph node is essential for host 
defense 
The egress of lymphocytes from the lymph node is essential for host 
immunity. When naïve T and B cells enter a lymph node and are unable to find 
their cognate antigen, these lymphocytes must exit the lymph node, and 
subsequently enter other lymphoid organs to continue their antigen surveillance 
program. Hence, T as well as B cell egress from the lymph node is essential for 
proper antigen/pathogen surveillance by naïve lymphocytes within the body 
(Cyster and Schwab, 2012; Schwab and Cyster, 2007), and disrupted egress might 
reduce the efficiency of the antigen surveillance program as well as delay the 
induction of the adaptive immune response.  
Finally, the proper regulation of egress timing is just as important as 
functional egress for host immune defense. Premature egress of activated 
lymphocytes may result in insufficient clonal expansion or, differentiation (Cyster 
and Schwab, 2012) to deal with the invading pathogen whereas delayed egress 
might provide the invading pathogen with an opportunity to replicate and thus, 





Atherosclerosis is a progressive disease characterized by the accumulation of 
lipids, cells and fibrous elements in large arteries thereby leading to a decrease in 
vessel lumen size (Libby, 2002). This disease is the single most important 
contributor to cardiovascular disease (Hansson et al., 2006), a leading cause of 
death and illness in developed countries (Murray and Lopez, 1997). 
Atherosclerosis begins in medium and large arteries at regions of low laminar 
shear stress as well as irregular blood flow (Libby, 2002). The deposition of 
modified lipoprotein particles onto arterial intima such as oxidized low density 
lipoprotein (oxLDL) (Camejo et al., 1998; Skalen et al., 2002) result in the 
inflammatory activation of arterial endothelial cells. The activated endothelial 
cells increase the expression of leukocyte adhesion molecules such as vascular 
cell adhesion molecule-1 (Eriksson et al., 2001) which allows for the recruitment 
of leukocytes such as T cells and monocytes to the arterial endothelium. The 
monocytes enter the arterial intima through the interaction between CCR2 on the 
monocyte cell surface and monocyte chemotactic protein-1 in intima.  
Inside the intima, recruited monocytes differentiate into macrophages under 
the influence of macrophage colony stimulating factor and upregulate the 
expression of scavenger receptors (Clinton et al., 1992; Rosenfeld et al., 1992). 
The macrophages internalize the deposited oxLDL with the aid of the scavenger 
receptors thereby giving rise to foam cells. In addition, the macrophages also 
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produce growth factors and cytokines and these processes result in the formation 




 mouse  
1.9.1 The apoE
-/-
 mouse is a suitable animal model of atherosclerosis 
The animal model used in this study was the C57 BL/6 mice deficient in 
apolipoprotein E (apoE
-/-
 mice). Apolipoprotein E (apoE) is mainly synthesized in 
the liver and it is a surface component of lipoprotein particles. ApoE at the 
lipoprotein particle surface functions as a ligand for lipoprotein receptors that 
mediate the recognition, and uptake of lipoprotein particles from the circulation 
by cells that express lipoprotein receptors. Therefore, a deficiency in apoE within 
the organism leads to the accumulation of chylomicrons and very low density 
lipoprotein remnants in plasma (Breslow, 1993). 
ApoE deficiency in mice thus results in increased plasma cholesterol levels 
and the development of atherosclerotic plaques in arteries at sites that are 
normally affected during human atherosclerosis (Breslow, 1993; Nakashima et al., 
1994). In addition, apoE
-/-
 mice develop the full spectrum of lesion types that 
occur during human atherogenesis. Lesions begin to form at 6 weeks of age, fatty 
streaks appear at 10 weeks of age, intermediate lesions at 15 weeks of age and 
advanced fibrous plaques associated with advanced atherosclerosis after 20 weeks 
of age. Finally, feeding apoE
-/-
 with a high fat, cholesterol rich diet (also called 
“western diet”) accelerates the development of atherosclerotic lesions (Nakashima 
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et al., 1994), and this acceleration also closely resembles human atherosclerosis 
where a diet rich in saturated fat and cholesterol results in an exacerbation of the 
disease (Hirata et al., 1994). 
Therefore, these features of the apoE
-/-
 mice demonstrate that it is a suitable 








 mice also exhibit other systemic defects beyond atherosclerosis such 
as dyslipidemia, tissue swelling, lymphatic vessel ‘leakiness’, decreased drainage 
of lymph fluid from tissues and skin inflammation (Angeli et al., 2004; Lim et al., 
2009). Contact hypersensitivity (CHS) and delayed type hypersensitivity (DTH) 
studies in apoE
-/-
 mice also demonstrate the presence of hypertrophic lymph nodes 
as well as poor immune priming in these mice. The poor immune priming in 
apoE
-/-
 mice was due to impaired migration of DCs to the skin draining lymph 
nodes, and treatment of dyslipidemia in apoE
-/-
 mice by high density lipoprotein 
(HDL) administration restores DC migration to the lymph node as well as 
immune priming (Angeli et al., 2004).  
 Finally, apoE
-/-
 mice also demonstrate increased susceptibility to pathogens 
such as fungi (Netea et al., 1997), bacteria (de Bont et al., 2000; Martens et al., 
2008; Roselaar and Daugherty, 1998) and viruses (Ludewig et al., 2001). ApoE
-/-
 
mice infected with LCMV exhibit delayed clearance of virus from the spleen and 
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lymph nodes, impaired activation of virus specific CD8 cytotoxic T cells as well 
as impaired recruitment of these CD8 T cells into the blood and liver (Ludewig et 
al., 2001). Studies of Mycobacterium tuberculosis infection in apoE
-/-
 mice 
demonstrate that these mice had a higher bacteria load in the lungs, and exhibited 
weak immune priming of the adaptive response against the bacteria (Martens et 
al., 2008) while infection with Klebsiella pneumoniae revealed that apoE
-/-
 mice 
had a higher mortality in response to the infection, increased bacteria load in 




 mice exhibit other systemic defects beyond atherosclerosis 
and it is possible that the various defects might be loosely related. 
 
1.10 Rationale of study 
Lymph nodes play an important role in host defense against pathogens by 
facilitating the induction of adaptive immune responses, and this role of the 
lymph node requires both proper organization of the lymph node 
microenvironment and leukocyte trafficking into as well as out of the lymph node.  
Previous studies have demonstrated that apoE
-/-
 mice develop hypertrophic 
lymph nodes and are more susceptible to pathogens such as bacteria and viruses 
with increased mortality, increased pathogen load as well as impaired induction of 
the adaptive immune response. Hence, it is of interest to characterize better lymph 
node hypertrophy observed in apoE
-/-
 mice and the underlying mechanism(s) of its 
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development as well as maintenance. The knowledge obtained will further our 
understanding of how the lymph node influences and contributes to functional 
host immunity. This may enable the future manipulation of lymph node processes 
to achieve desirable therapeutic outcomes during disease.  
ApoE
-/-
 mice also exhibit dyslipidemia together with dysfunctional lymphatic 
vessels. Therefore, apoE
-/-
 mice also allow us to study how dyslipidemia affects 
lymphatic vessels in the lymph node and the impact of dysfunctional lymphatic 
vessels on lymph node processes, functions and cellular trafficking into and out of 
the organ. The knowledge obtained from such studies may be applied to the 
treatment of lymphedema, autoimmune diseases or other diseases that involve the 
human lymphatic vasculature. 
 
1.11 Objectives 
Therefore, the objectives of the study are: 
1. Characterize the lymph node hypertrophy in apoE-/- mice, and 
association with atherosclerosis  
2. Determine the mechanism(s) of formation and understand how 
hypertrophic lymph nodes can contribute to impaired host immunity. 
3. To determine whether lymph node hypertrophy can be therapeutically 
reversed or, reduced in severity through the amelioration of 




2. Materials and Methods 
2.1 Animals 
Male CD45.2 C57 BL/6 mice deficient in apolipoprotein E (apoE
-/-
 mice) 
were obtained from The Jackson Laboratory (Bar Harbor, ME). The control mice 
were male CD45.2 wild type C57 BL/6 (WT) mice purchased from the Centre for 
Animal Resources (National University of Singapore) and were matched for age 
and diet. All mice were given a chow diet (18% protein and >5% fat, Harlan Teklad, 
Madison, WI) post wean until 6 weeks of age. At 6 weeks of age, the diet was 
switched to a high fat and cholesterol rich diet (also called “western diet”) 
containing 21.2% fat and 0.2% cholesterol (Harlan Teklad). The mice were then 
maintained on the western diet until sacrifice. Male and female CD45.1 WT C57 
BL/6 mice were also used in this study as donor or recipient mice for adoptive 
transfer experiments. 
All mice were housed under specific pathogen free conditions with 
unrestricted access to food and water in the animal housing unit of the National 
University of Singapore. All studies were performed under protocols approved by 
the Institutional Animal Care and Use Committee (IACUC) of the National 
University of Singapore.  
 
2.2 Ezetimibe treatment 
Male apoE
-/- 
and WT mice were fed a chow diet post wean and subsequently 
switched to a western diet at 6 weeks of age as described  in Section 2.1. When 
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the mice were 13 to 16 weeks of age, each phenotype (apoE
-/- 
and WT) was 
divided into 2 groups; ezetimibe treated or non-treated Group. The ezetimibe 
treated apoE
-/-
 and WT groups were treated daily with ezetimibe (Kemprotec) via 
oral gavage at a dose of 5mg of ezetimibe per kg of body weight dissolved in 
200µl of corn oil. The non-treated groups were given 200µl of corn oil daily by 
oral gavage regardless of body weight. The body weight of all mice was measured 
every fortnight and ezetimibe treatment was conducted for 12 weeks prior to 
sacrifice.  
 
2.3 Quantification of CCL21 by enzyme-linked immunoabsorbent assay 
(ELISA) 
Lymph node samples used for the CCL21 ELISA (R&D Systems) assay were 
taken from 1 brachial and 1 axillary lymph node per WT or apoE
-/-
 mouse. All 
lymph node samples were homogenized in lysis buffer (RIPA buffer, Sigma 
Chemicals) supplemented with a protease inhibitor cocktail (Roche Diagnostics). 
Once homogenization was complete, the lysate was centrifuged at 14000g, 10 
minutes at 4°C. The supernatant was then collected and used for the CCL21 
ELISA assay. All samples were diluted using the reagent diluent provided in the 
assay kit and the, ELISA assay was done according to the manufacturer’s 





2.4 Hybridoma cell culture and purification of secreted antibodies 
Rat hybridoma cells (MEL-14, American Type Culture Collection) that 
secrete anti-mouse CD62L monoclonal antibody were cultured in this study. The 
hybridoma cells were first cultured in complete DMEM cell culture media until 
the cells have reached a log phase in growth. At the log phase of growth, these 
cells were cultured in 1X hybridoma serum free media (Gibco), and the media 
supernatant was collected for purification of anti-mouse CD62L antibody by fast 
protein liquid chromatography. Purified antibodies were stored at -80°C until use 
and the amount of antibody obtained was measured with a BCA protein assay kit 
(Thermo Scientific) according to the manufacturer’s protocol. 
 
2.5 Immunofluorescence microscopy 
All antibodies used for immunofluorescence microscopy in this study are 
listed in Table 2.1. 
 




Affinity purified α- 
mouse B220 












Rabbit IgG Abcam 1.67 
Primary 
antibody 
Affinity purified α- 
mouse Ki67 












purified α-goat IgG 




affinity purified  
α-rabbit IgG 
Donkey IgG Jackson  1.67 
Secondary 
antibody 




Goat IgG Jackson  1.25 
Secondary 
antibody 
Alexa Fluor 647 
conjugated affinity 
purified α-rat IgG 




Table 2.1 List of antibodies used in immunofluorescence microscopy 
 
2.5.1 Preparation of paraformaldehyde fixed tissue sections for 
immunostaining 
Skin draining lymph nodes were excised from the mice after sacrifice and 
fixed overnight in 2% paraformaldehyde / 30% sucrose at 4°C. After fixation, the 
lymph nodes were washed 2 times, 30 minutes per wash, in 1X phosphate 
buffered saline (PBS) / 30% sucrose. The washed tissues were then embedded in 
tissue freezing medium (Sakura Finetek) and snap frozen on dry ice. Embedded 
lymph nodes were cut into 7μm sections at -20°C with a cryostat (Leica 
CM3050S) and adhered onto Polysine
TM 
slides (Thermo Fisher Scientific). The 
slides were stored at -35°C and warmed up at room temperature for 45 minutes 
prior to immunostaining.  
All thawed slides were first hydrated in 1X PBS for 10 minutes. The slides 
were subsequently blocked with 1X PBS / 0.2% bovine serum albumin (BSA) for 
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10 minutes and then, washed 2 times in 1X PBS, 5 minutes per wash. Tissue 
sections were then incubated overnight in a humid chamber with 80μl of primary 
antibody mix diluted in 1X PBS / 1% normal mouse serum at 4°C. The next day, 
all slides were washed 4 times with 1X PBS, 4 minutes per wash. The samples 
were next incubated with 80μl of secondary antibody mix diluted in 1X PBS / 1% 
normal mouse serum at room temperature, for 1 hour in a humid chamber and 
protected from light. At the end of 1 hour, the slides were again washed for 4 
times with 1X PBS, 4 minutes per wash.  
Finally, a cover slip was mounted onto the slide with a few drops of 
fluorescent mounting media (Dako) and the mounted slides were dried and sealed 
with nail polish. All sealed slides were stored at 4°C until used for viewing with a 
fluorescence microscope (AxioImager Z1, Axiocam HRM camera; Carl Zeiss 
Micro Imaging, Inc., Jena, Germany) with Axiovision software (version 4.8; Carl 
Zeiss Micro Imaging, Inc.). The exposure time was held constant for each 
magnification and wavelength. 
 
2.5.2 Preparation of fresh, acetone fixed tissue sections for immunostaining 
Some skin draining lymph nodes were fixed in acetone instead of 
paraformaldehyde. These samples were embedded fresh into tissue freezing 
medium (Sakura Finetek) and snap frozen on dry ice. The embedded lymph node 
were subsequently sectioned, adhered onto slides, stored and warmed up in the 
same manner as paraformaldehyde fixed samples.  
36 
 
After thawing, the sections were first fixed in ice cold acetone for 15 minutes 
at -20°C and then washed twice in 1X PBS, 5 minutes per wash. The fixed 
sections were subsequently blocked with BSA, incubated with primary and 
secondary antibodies with washing after each step and the slides were mounted 
with a coverslip, dried and sealed as described in Section 2.5.1. All samples were 
also viewed and captured with the same fluorescence microscope and Axiovision 
software as described in Section 2.5.1. The exposure time was also held constant 
for each magnification and wavelength. 
 
2.5.3 Quantification of lymphatic vessel area by immunofluorescence analysis 
Microscope images used for this analysis were acquired from 6 representative 
lymph node sections per mouse. Within each section, the area of 15 lymphatic 
vessels in the cortex region and 10 lymphatic vessels in the medulla region were 
quantified. Therefore, a total of 90 (15 vessels X 6 sections) cortical lymphatic 
vessels and 60 (10 vessels X 6 sections) medullary lymphatic vessels were 
sampled per mouse. The mean cortical and medullary lymphatic vessel area was 
then calculated for each mouse, and subsequently compared in our statistical 
analysis. All lymphatic vessel areas were obtained by using the ‘measure’ tool of 







2.6 Cell isolation 
2.6.1 Isolation of lymphocytes from lymph nodes and the spleen 
Single cell suspensions containing T and B cells were obtained from skin 
draining lymph nodes by first teasing the lymph nodes apart in hank’s balanced 
salts solution (HBSS) with 27G needles. The lymph node fragments were then 
pressed through a 70µm cell strainer (BD Falcon) with the rubber plunger of a 
3ml syringe and the resulting single cell suspension was collected in a 15ml 
conical round bottom tube (BD Falcon). The cells were then centrifuged at 311g 
for 5 minutes, 4°C and re-suspended in MACS buffer for the enumeration of 
viable cells. These procedures were done in a BSC hood if sterile conditions were 
required. 
Single T and B cell suspensions were also obtained from the spleens of donor 
mice for adoptive transfer experiments and were isolated using the same the 
protocol as the lymph nodes. However, an extra step of red blood cell lysis was 
performed after obtaining the single cell suspensions. Red blood cell lysis was 
done by first incubating the cells in 5-10ml of red blood cell lysis buffer for 5 
minutes on ice. The lysis reaction was stopped after 5 minutes by washing the 
cells twice with excess HBSS. The resulting cell suspension was finally filtered 
through a new 70µm cell strainer and re-suspended in MACS buffer for cell 
counting. T and B cell isolation from the spleen was also done in a BSC hood if 




2.6.2 Isolation of LECs from lymph nodes 
Excised skin draining lymph nodes were first digested with 4mg/mL 
collagenase IV (Roche) in calcium and magnesium free HBSS at 37˚C for 45 
minutes with gentle agitation. After 45 minutes, EDTA was added to the digestion 
mixture to a working concentration of 10mM and the lymph nodes were further 
digested for 5 minutes at 37˚C in a final digestion step. Single cell suspensions 
containing the LECs were then obtained from the digested lymph nodes as 
described in Section 2.6.1 and a viable cell count was also performed. 
 
2.6.3 Isolation of lymphocytes from lymph 
All mice involved in lymph harvest experiments were fasted overnight prior to 
sacrifice and lymph was collected as described by Matloubian et al. (Matloubian 
et al., 2004). The mouse was first anaesthetized and then placed under a dissecting 
microscope (Olympus). The peritoneal cavity was exposed ventrally and the 
cysterna chili identified with the aid of the dissecting microscope. 40µl of lymph 
was subsequently drawn from the cysterna chili with the use of extended length 
gel-loading pipette tips (Neptune Scientific), and used for flow cytometry. All 
mice were finally euthanized by cervical dislocation and other tissues were 
harvested where necessary.  
 
2.7 Flow cytometry 
All antibodies used for flow cytometry are listed in Table 2.2. 
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Antibodies Isotype Source 
Concentration 
(μg/ml) 




eFluor® 450 conjugated α-
mouse CD4 
Rat IgG2a  eBioscience 1.00 
FITC conjugated α-mouse B220 Rat IgG2a eBioscience 2.50 
PerCP–Cy5.5 conjugated α-
mouse B220 
Rat IgG2a BD Pharmingen 2.00 
Pacific blue conjugated α-mouse 
B220 
Rat IgG2a Invitrogen 2.00 
Biotin conjugated α-mouse 
CD45.1 
Mouse IgG BD Pharmingen 2.50 
PerCP-Cy5.5 conjugated α-
mouse 45.2 
Mouse IgG eBioscience 1.00 
PE conjugated α-mouse CD44 Rat IgG2a eBioscience 0.34 
PerCP-Cy5.5 conjugated α-
mouse CD62L 
Rat IgG2a eBioscience 0.40 
Monoclonal α-mouse CD31 Rat IgG2a AbD Serotec 2.00 
Monoclonal α-mouse podoplanin 
Syrian hamster 
IgG 
DSHB, University of 
Lowa 
5.00 
PE conjugated α-syrian hamster Goat IgG Caltag Laboratories 1.00 
APC conjugated α-rat Goat IgG Invitrogen 0.50 
Streptavidin conjugated PE NA Invitrogen 0.20 
Streptavidin conjugated PcP-
Cy5.5 
NA eBioscience 0.67 
 





2.7.1 Surface staining of T and B cells for flow cytometry analysis 
Single cell suspensions were first seeded into a 96-well round bottom plate 
and centrifuged at 311g for 5 minutes at 4°C. The cells were then re-suspended in 
100µl of MACS buffer containing the fluorochrome conjugated primary antibody 
mix and incubated in the dark for 30 minutes at 4°C. Following primary antibody 
staining, the cells were washed 3 times with 1X PBS, and fixed with 200µl of 1% 
formalin. Finally, the cell suspensions were stored in the dark at 4°C until flow 
cytometry analysis.  
 
2.7.2 Staining for CCR7 surface expression on T cells for flow cytometry 
analysis 
The T cell CCR7 surface expression staining protocol was slightly modified 
with CCR7 being stained first before other surface markers. Cell suspensions 
were first incubated with 100µl of MACS buffer containing rat anti-mouse CCR7 
antibody, 1% normal mouse serum and 1% normal rat serum for 1 hour at 37°C. 
The cells were then washed 3 times with 1X PBS. Next, the cells were incubated 
with 100µl of MACS buffer containing anti-rat IgG secondary antibody, 1% 
normal mouse serum and 1% normal goat serum for 15 minutes at 4°C in the 
dark. The cells were again washed with 1X PBS. Last of all, the cells were stained 





2.7.3 Surface staining of LECs for flow cytometry analysis 
Surface staining of LECs was done in 2 steps. In the 1
st
 step, the cell 
suspensions were incubated with 100µl of MACS buffer containing the non-
conjugated primary antibody mix for 30 minutes at 4°C. The cells were then 
washed 3 times with 1X PBS as described in Section 2.7.1. In the 2
nd
 step, the 
cells were incubated with 100µl of MACS buffer containing the fluorochrome-
conjugated secondary antibody mix for 15 minutes, 4°C in the dark. Finally, the 
cells were washed 3 times with 1X PBS and subsequently analyzed by flow 
cytometry without fixation. 
 
2.7.4 Flow Cytometry data acquisition and analysis 
Flow cytometry quantification for all samples was either done on a FACS 
Calibur cytometer (BD Biosciences) with Cell Quest data acquisition software or 
on a Cyan cytometer (Dako) with Summit data acquisition software. All acquired 
data were analyzed with Flowjo software (Treestar).   
 
2.8 Adoptive transfer of lymphocytes 
2.8.1 Carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling of 
donor cells for adoptive transfer 
Single cell suspensions were obtained under sterile conditions from harvested 
spleen as well as lymph nodes of donor mice, and a viable cell count was done as 
described in Section 2.6.1. The cells were then re-suspended in sterile 1X PBS / 
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0.1% BSA to a concentration of 1 X 10
7
 cells/ml. Stock CFSE (Invitrogen) 
solution was subsequently added to the cell suspension to a final concentration of 
1µM and the cells were labeled with CFSE in a waterbath at 37°C for 5 minutes 
in the dark with frequent mixing. The CFSE labeling reaction was then quenched 
by washing the cell suspensions twice with excess ice cold complete RPMI-1640 
culture medium. Finally, a viable cell count was again done.      
 
2.8.2 Long term adoptive transfer of lymphocytes  
Long term adoptive transfers of WT CD45.1 donor cells into apoE
-/-
 and WT 
CD45.2 recipient mice were done to determine the egress of lymphocytes from 
the skin draining lymph nodes of WT and apoE
-/-
 mice. The protocol for this long 
term adoptive transfer assay was adopted from Tan et al. (Tan et al., 2012), and 
the schematic for this long term adoptive transfer is shown in Figure 2.1  
 
 
Figure 2.1 - Schematic for long term adoptive transfer of lymphocytes. 
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At T= -24 hours, single cell suspensions were obtained under sterile 
conditions from skin draining lymph nodes and spleens of 6-10 weeks old WT 
CD45.1 donor mice as described in Section 2.6.1. Both male and female WT 
CD45.1 mice were used as donor mice. WT CD45.1 donor cells were suspended 
in sterile 1X PBS, and 20 X 10
6
 donor cells in 200µl of 1X PBS was adoptively 
transferred into each 22-28 weeks old WT and apoE
-/-
 CD45.2 recipient mice via 
tail vein injection. All recipient mice were rested overnight after tail vein 
injection. 
The next day at T= 0 hours, half of the recipient mice in each group were 
euthanized and the brachial lymph nodes were excised for flow cytometry 
analysis. The numbers of WT total donor cells, donor T cells as well as donor B 
cells present in recipient brachial lymph nodes were quantified by flow cytometry 
and were used to calculate the T0 average value for each donor cell population as 
demonstrated in Figure 2.2.  
The remaining recipient mice were injected intra-peritoneally with 200µg of 
α-CD62L antibody to block further entry of donor cells into the recipient lymph 
nodes. These recipient mice form the T20 group and were euthanized 20 hours 
after injection. The brachial lymph nodes were also excised for flow cytometry, 
and the number of WT total donor cells, donor T cells as well as donor B cells 
present in the brachial lymph nodes was also quantified. The cell counts obtained 
are known as the T20 values and were used to calculate the respective egress index 
for all donor cell types in each recipient mouse. The calculation of the egress 





Figure 2.2 Calculation of the egress index using donor T cells as an example. A smaller value 
(≈0) indicates higher egress while a larger value (≈1) indicates a block in egress. All cell 





A reverse long term adoptive transfer of apoE
-/-
 CD45.2 and WT CD45.1 
donor cells into WT CD45.2 recipient mice was also done in this study and the 
schematic of this transfer is shown in Figure 2.3.  
 
 
Figure 2.3 - Schematic for reverse long term adoptive transfer of lymphocytes. 
 
All egress index calculations, and experimental steps in the reverse adoptive 
transfer was identical with the earlier long term adoptive transfer (Figures 2.1 
and 2.2) except: 
1. The donor mice were 22-28 weeks old WT CD45.1 and apoE-/- CD45.2 
mice. All donor cells were labeled with CFSE as described in Section 
2.8.1 before adoptive transfer.  
2. The recipient mice were 6 weeks old WT CD45.2 mice and each recipient 
mice received 20 million CFSE labeled donor cells in 200µl of sterile 1X 
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PBS which consist of 10 million WT CD45.1 donor cells and 10 million 
apoE CD45.2
-/-
 donor cells. 
3. 100µg of α-CD62L antibody was injected into the T20 WT recipient mice 
instead of 200µg. 
 
2.8.3 Short term adoptive transfer of lymphocytes 
Short term adoptive transfers of WT CD45.1 donor cells into apoE
-/-
 and WT 
CD45.2 recipient mice were done to determine lymphocyte entry into skin 
draining lymph nodes of WT and apoE
-/-
 mice. The protocol for this short term 
transfer assay was also adapted from Tan et al. (Tan et al., 2012).  
 
 
Figure 2.4 - Schematic for short term adoptive transfer of lymphocytes. 
 
Single cell suspensions were obtained under sterile conditions from skin 
draining lymph nodes and spleens of 6-10 weeks old male as well as female WT 
CD45.1 donor mice as described in Section 2.6.1. The WT CD45.1 donor cells 
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were then re-suspended to a concentration of 20 X 10
6
 cells in 200µl of sterile 1X 
PBS, and each 22-28 weeks old WT as well as apoE
-/-
 CD45.2 recipient mice 
received 200µl of this donor cell suspension via tail vein injection.  
All recipient mice were allowed to rest for 150 minutes after adoptive transfer. 
At the end of 150 minutes, the recipient mice were euthanized and the brachial 
lymph nodes were obtained for flow cytometry analysis. Flow cytometry was 
used to quantify the number of WT CD45.1 total donor cells, donor T cells and 
donor B cells present in the recipient brachial lymph nodes. The various donor 




Like the long term adoptive transfer assays, a reverse short term adoptive 
transfer of apoE
-/-
 CD45.2 and WT CD45.1 donor cells into WT CD45.2 recipient 
mice was also done and the schematic of this reverse short term transfer is shown 
in Figure 2.5. 
 
 
Figure 2.5 - Schematic for reverse short term adoptive transfer of lymphocytes. 
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All steps in the reverse short term transfer were identical to the short term 
transfer (Figure 2.4) except:  
1. The donor mice were 22-28 weeks old WT CD45.1 and apoE-/- CD45.2 
mice. All donor cells were also labeled with CFSE before transfer as 
described in Section 2.8.1 
2. Each recipient mouse received 20 million donor cells in 200µl of sterile 
1X PBS through tail vein injection. The 20 million donor cells consist of 




3. The recipient mice used were 6 weeks old WT CD45.2 mice. 
4. Each WT recipient sample was divided into 2 tubes for separate staining, 
and quantification of WT and apoE
-/-
 donor T, and B cells. 
 
2.9 Quantification of S1P in skin draining lymph nodes, lymph fluid and 
plasma by mass spectrometry 
S1P was extracted from the lymph nodes, lymph and blood of apoE
-/-
 as well 
as WT mice and measured by mass spectrometry according to the protocol 





2.9.1 Collection of lymph node, lymph and plasma samples for S1P 
quantification 
The skin draining brachial lymph node was used for the quantification of S1P 
in lymph nodes. 1 brachial lymph node was excised from the right side of the 
mice immediately after sacrifice and placed in a new eppendorf tube. The lymph 
node was snap frozen in liquid nitrogen and stored at -80°C until use.  
For lymph samples, 25µl of lymph was drawn from the cysterna chyli as 
described in Section 2.6.3 and collected into a new eppendorf tube. The lymph 
samples were then centrifuged at 14,000g for 10 minutes at 4°C and the 
supernatant was collected for subsequent S1P extraction. Special care was taken 
to avoid mixing lymph node and lymph samples with blood. 
The S1P level in the blood was measured from plasma samples. Whole blood 
was drawn from the mice via cardiac puncture immediately after sacrifice and 
mixed well with 50µl of 100mM EDTA in an eppendorf tube. The blood-EDTA 
mixture was then centrifuged at 14,000g, 4°C for 10 minutes and 10µl of plasma 
was obtained from the supernatant. Special care was also taken to minimize red 







2.9.2 Extraction of S1P from lymph and plasma 
S1P was extracted from lymph and plasma samples according to this protocol: 
1. 10µl of internal standard 13C2D2 S1P and 90µl of methanol was first added 
to 10µl of plasma or 5µl of internal standard 
13
C2D2 S1P and 90µl of 
methanol was added to 5µl of lymph. 
2. The lymph or plasma samples were then mixed in a thermal mixer for 20 
minutes at 4°C. After mixing, the samples were centrifuged at 14000g for 
10 minutes, 4°C and the supernatant was collected. 
3.  The supernatants of plasma and lymph samples were then speed-dry in a 
centrifugal evaporator (RC1010, Thermo Scientific) for 2 hours and upon 
drying, the samples were reconstituted with 100µl of methanol.  
4. 10µl of trimethylsilyldiazomethane (TMS-Diazomethane) was then added 
to each sample to methylate the sample and the methylation reaction was 
performed for 20 minutes at room temperature in a thermo mixer.  
5. The methylation reaction was stopped after 20 minutes by the addition of 
1µl of acetic acid. The samples were again speed-dry in the centrifugal 
evaporator for 2 hours. 
6. Finally, lymph samples were reconstituted with 50µl of mobile phase B 
while plasma samples were reconstituted with 100µl of mobile phase B. 
The reconstituted samples were then injected into the liquid 
chromatography–mass spectrometry system.  
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2.9.3 Extraction of S1P from lymph nodes 
S1P was extracted from the brachial lymph nodes according to this protocol: 
1. Lymph nodes were first weighed in 1.5ml eppendorf tubes and then mixed 
with 190µl of methanol + 10µl of internal standard 
13
C2D2 S1P.  
2. The lymph node samples were subsequently sonicated at 4°C for 30 
minutes (Instant Analytik) and after sonication was complete, the lysate 
was centrifuged for 10mins, 14000g at 4°C. The supernatant was collected 
and then speed dry in a centrifugal evaporator for 2 hours. 
3. The dried samples were reconstituted with 100µl methanol and methylated 
with 10µl of TMS-Diazomethane. The methylation reaction was done for 
20 minutes in a thermo mixer at room temperature. After 20 minutes, the 
methylation reaction was stopped by adding 1µl of acetic acid to the 
samples. 
4. Finally, the samples were speed-dry for 2 hours and upon drying, were 
reconstituted in 100µl of mobile phase B before injection into the liquid 
chromatography–mass spectrometry system. 
 
2.9.4 Liquid chromatography – mass spectrometry 
All WT and apoE
-/-
 plasma, lymph node and lymph samples were first 
fractionated by high performance liquid chromatography (HPLC 1200 Infinity 
Series, Agilent Technologies) and the amount of S1P within the S1P fraction was 
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measured by mass spectrometry (Agilent 6540 UHD Accurate-Mass Q-TOF with 
ChipCube, Agilent Technologies).  
These are the settings for high performance liquid chromatography: 
 
Table 2.3 – Settings for high performance liquid chromatography 
Mobile phase A 
50% acetonitrile + 50% water containing 25mM 
ammonium formate, pH4.6 
Mobile phase B 
95% acetonitrile + 5% water containing 25mM 
ammonium formate, pH4.6 
Cap pump flow rate 4µl / minute 
Nano pump flow 
rate 
0.4µl / minute 
Nano pump gradient 
0-1.5 minutes 100% B, 1.5-8.5 minutes 40% B, 8.5-10.5 
minutes 30% B, 11.5-13 minutes 0% B, 13.1-19 minutes 
100% B 
Injection volume 1µl 
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For mass spectrometry, the mass spectrometer was operated in targeted 
MS/MS mode and these are the settings: 
ChipCube operation 
mode 
Backflush mode. The column was switched from 
enrichment to analysis at 1.5 minutes after injection 
of the sample 
Ion mode 
Positive. 
Gas temperature at 300°C, Fragmentor at 175V, 




MS/MS acquisition rate 2.5 spectra/second 
 






2.10 Lymphangiography  
40 weeks old WT and apoE
-/-
 mice were used for lymphangiography studies. 
These mice were first anesthetized and then injected subcutaneously with Evan’s 
blue dye at the left footpad.  Following injection, the mice were rested for 30 
minutes to allow the dye to travel through the lymphatic vessels. The injected 
mice were sacrificed after 30 minutes by carbon dioxide asphyxiation. The mice 
were dissected through 2 different methods to locate the lymphatic vessels and 
lymph nodes of interest; removal of the skin and fascia tissue facilitates the 
location of popliteal, inguinal, and axillary lymph nodes together with their 
associated lymphatic vessels while removal of the intestines facilitated the 
location of iliac and renal lymph nodes, and their associated lymphatic vessels. 
 
2.11 Statistical analysis  
All values in this study were expressed as the mean of n samples ± SEM. 
Experimental data with 2 groups were analyzed by unpaired double tailed t-test 
while data with 3 groups were first compared using analysis of variance 
(ANOVA) followed by a post double tailed t-test with Bonferroni correction for 
pair wise comparisons. Finally, all statistical analysis were done using the Prism 5 
software (Graphpad Software,Inc,) and values of p<0.05 were considered to be 






3.1 Summary of the experimental approach 
All experiments in the results section were designed to answer different 
questions of interest, and address the objectives listed in Section 1.11. In addition, 
the experiments were also grouped together according to the goals that they 
address. Figure 3.1 shows the summary of the experimental approach. 
 
 
Figure 3.1 Summary of the experimental approach.  
56 
 
3.2 Characterization of lymph node hypertrophy  
3.2.1 The development of lymph node hypertrophy in apoE
-/-
 mice is 
associated with the progression of atherosclerosis disease 
To investigate the morphological, and functional changes in hypertrophic 
lymph nodes from apoE
-/-
 mice and their relationship with impaired immunity 
first requires the verification of its development, and subsequent presence during 
the progression of atherosclerosis. Therefore, we quantified the cellularity of skin 
draining lymph nodes in apoE
-/-
 mice at 6 weeks of age (where atherosclerosis is 
minimal), at 22-28 weeks of age (where atherosclerosis is well established) 
(Breslow, 1996) and in non-diseased, age-matched WT control mice.  
 
Figure 3.2 Hypertrophic lymph nodes in 22-28 weeks old apoE
-/-
 mice develop in association 
with the progression of atherosclerosis disease. Lymph node cellularity results were expressed 
as fold increase in apoE
-/-
 over WT. 6 weeks old apoE
-/-
 mice did not display a significant fold 
increase over WT mice (0.98±0.14 fold increase) whereas 22-28 weeks old apoE
-/-
 mice displayed 
a significant 5.27 ± 0.47 fold increase over WT.  
Results for 22-28 weeks old apoE
-/-
 mice were pooled from 5 independent experiments with 3-4 
mice per group in each experiment while results for 6 weeks old apoE
-/-
 mice were pooled from 2 
independent experiments with 3 mice per group in each experiment. A representative experiment 
is shown in Figure 5.1 of Appendix B. 
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At 6 weeks of age, apoE
-/-
 mice did not display a significant fold increase in 
lymph node cellularity over WT control mice (0.98 ± 0.14 fold increase). 
Therefore, this demonstrated that lymph node hypertrophy did not occur in young 
apoE
-/-
 mice when atherosclerosis is minimal. However, at 22-28 weeks of age 
when atherosclerosis is well advanced and hypercholesterolemia is marked,  
apoE
-/-
 mice displayed a biologically significant fold increase in lymph node 
cellularity (5.27 ± 0.47 fold increase) over WT control mice (Figure 3.2).  
Therefore, the development and presence of hypertrophic lymph nodes in 22-
28 weeks old apoE
-/-
 mice is associated with hypercholesterolemia, and the 
progression of atherosclerosis disease within the mice.   
 




Having demonstrated the association of hypertrophic lymph nodes with 
atherosclerosis in 22-28 weeks old apoE
-/-
 mice, we subsequently characterized 
the changes that occur in these hypertrophic lymph nodes. Because lymphocytes 
are the major cellular components of the lymph node, we asked if both T and B 
cell populations are increased within hypertrophic lymph nodes and addressed this 
question through flow cytometry quantification of  lymphocytes in the lymph 
nodes of 22-28 weeks old WT and apoE
-/-
 mice.  





Figure 3.3 Both T and B cells are significantly increased in hypertrophic lymph nodes.        
(A) Representative gating strategy for T and B cells in lymph nodes of WT and apoE
-/-
 mice.    (B) 
Results are expressed as fold increase in apoE
-/-
 over WT. Both T (3.94 ± 0.32 fold increase) and 
B cells (10.92 ± 2.28 fold increase) were increased in hypertrophic lymph nodes, and the increase 
was biologically significant. 
Data was pooled from 5 independent experiments with 3-4 mice per group in each experiment. A 
representative experiment is also shown in Figure 5.2 of Appendix B. 
 









flow cytometry (Figure 3.3A). The results demonstrated that both T and B cells 





with a 3.94 ± 0.32 fold increase over WT for T cells and a 10.92 ± 2.28 fold 
increase over WT for B cells respectively (Figure 3.3B). The increase in both 
lymphocyte populations was biologically significant.  
Therefore, hypertrophic lymph nodes of 22-28 weeks old apoE
-/-
 mice display 
a significant increase in both T and B cell populations. 
 
3.2.3 CD4 and CD8 T cells are significantly increased in hypertrophic lymph 
nodes, and the CD4:CD8 ratio does not differ from WT mice 
Because CD4 and CD8 T cells are the main T cell subsets among the lymph 
node T cell population, we ask the question of whether both T cell populations 
were significantly increased in hypertrophic lymph nodes, and present at 
proportions similar to WT lymph nodes.  
To answer these questions, flow cytometry was also used to quantify the 
number of CD4 and CD8 T cells in the lymph nodes of 22-28 weeks old WT and 
apoE
-/-
 mice. In addition, the CD4:CD8 ratio within the skin draining lymph 
nodes of each mouse was compared for all WT and apoE
-/-
 mice to determine 
whether these T cell subsets are present in different proportions within 
hypertrophic lymph nodes of apoE
-/-






Figure 3.4 Both CD4 and CD8 T cells are significantly increased in hypertrophic lymph 
nodes, and their ratios do not differ from WT lymph nodes. (A) Representative gating strategy 
for CD4 and CD8 T cells. (B) Both CD4 (3.96 ± 0.37 fold increase) and CD8 T cells (3.05 ± 0.25 
fold increase) were increased in hypertrophic lymph nodes and the increase was biologically 
significant. (C) CD4:CD8 ratios did not significantly differ between WT and apoE
-/-
 mice (p = 
0.4947, n = 17 for both groups) 
Results are expressed as fold increase in apoE
-/-
 over WT and the data was pooled from 5 
independent experiments with 3-4 mice per group in each experiment. Finally, a representative 
experiment for CD4 and CD8 T cell counts is shown in Figure 5.3 of Appendix B. 
 









 for flow cytometry (Figure 3.4A). The results demonstrated that both CD4 
and CD8 T cells were increased in hypertrophic lymph nodes of apoE
-/-
 mice with 
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a 3.96 ± 0.37 fold increase over WT for CD4 T cells and a 3.05 ± 0.25 fold 
increase over WT for CD8 T cells. This increase was biologically significant 
(Figure 3.4B). Finally, a comparison of lymph node CD4:CD8 ratios between 
WT and apoE
-/-
 mice (Figure 3.4C) revealed that there was no significant 
difference between the CD4:CD8 T cell ratios of WT (0.96 ± 0.04, n= 17) and 
apoE
-/-
 mice (1 ± 0.44, n=17).  
Therefore, both CD4 and CD8 T cells are significantly increased in the 
hypertrophic lymph nodes of apoE
-/-
 mice, and the CD4:CD8 T cell ratio does not 
differ from WT mice.  
 
3.2.4 Hypertrophic lymph nodes do not display a significant increase over 
WT in CD4 and CD8 T cell activation 
Since CD4 and CD8 T cells may be further divided into effector, naïve and 
central memory T cells, we asked if the number of these various subpopulations 
was significantly increased in hypertrophic lymph nodes of apoE
-/-
 mice. Hence, 
we quantified the number of CD4 and CD8 effector, naïve and central memory 
cells for WT as well as apoE
-/-
 mice and expressed the results of each 
subpopulation as a percentage of the total CD4 or, CD8 T cell population so as to 
account for the increased cell counts of apoE
-/-
 hypertrophic lymph nodes. CD4 













 for effector cells 





Figure 3.5 CD4 and CD8 T cell activation is not significantly increased in hypertrophic 
lymph nodes of apoE
-/-














(B) The number of CD4 naïve, effector and central memory T cells (p=0.0821, 0.1045 and 0.2643 
respectively) did not significantly differ between lymph nodes of WT and apoE
-/-
 mice. (C) 
However, naïve CD8 T cells count were significantly decreased (*p=0.0020) and effector CD8 T 
cell counts significantly increased (*p=0.0035) in hypertrophic lymph nodes of apoE
-/-
 mice but 
this changes were not believed to be biologically significant. No significant difference was 
observed between WT and apoE
-/-






Our results (Figure 3.5B) demonstrated that the percentage of naïve CD4 T 
cells did not differ between WT (73.23 ± 3.37%, n=4) and apoE
-/-
 mice (65.70 ± 
1.97%, n=5). No significant difference was also observed for central memory 
CD4 T cells between WT (8.45 ± 1.07%, n=4) and apoE
-/-
 mice (10.11 ± 0.87%, 
n=5) as well as for effector CD4 T cells between WT (6.62 ± 1.34%, n=4) and 
apoE
-/-
 mice (9.42 ± 0.82%, n=5). Thus, there were no changes in CD4 T cell 
subpopulations in hypertrophic lymph nodes of apoE
-/-
 mice. 
However, our results (Figure 3.5C) demonstrated that the percentage of naïve 
CD8 T cells was significantly decreased in apoE
-/-
 (57.98 ± 1.32%, n=5) as 
compared to WT mice (67.23 ± 1.41%, n=4). This decrease in naïve CD8 T cells 
was accompanied with a significant increase in effector CD8 T cells in apoE
-/-
 
(8.51 ± 0.64%, n=5) over WT mice (5.15 ± 0.30%, n=4) but no difference was 
observed in the number of central memory CD8 T cells between WT (17.58 ± 
0.49%, n=4) and apoE
-/-
 mice (20.23 ± 2.01%, n=5). Although there was a 
significant decrease in naïve CD8 T cells, and a significant increase in effector 
CD8 T cells of apoE
-/-
 lymph nodes, the difference between WT and apoE
-/-
 was 
small and hence, we did not consider the change to be biologically significant.  
Therefore, there are no significant alterations in CD4 and CD8 T cell 
activation within hypertrophic lymph nodes of apoE
-/-






3.2.5 Hypertrophic lymph nodes do not exhibit a disruption in the general 
organization of the lymph node microenvironment 
We next focused on the general organization of the lymph node 
microenvironment within hypertrophic lymph nodes and asked whether this 
organization was disrupted. To answer this question, we examined lymph node 
sections of WT and apoE
-/-
 mice by immunofluorescence microscopy.  
Lymph node sections of apoE
-/-
 and WT mice were stained with anti-TCRβ, 
anti-B220 antibodies to visualize the T and B cells respectively. In addition, the 
Mosaic X / autostitch function of the Carl Zeiss Z1 microscope was used to 
generate an overall image of the lymph node through automatic acquisition and 
merger of multiple fields of view with a 15% overlay between adjacent fields.  
The microscope images revealed that B cell follicles of hypertrophic lymph 
nodes were located beneath the subcapsular sinus (Figure 3.6, Region A) and in 
the outer cortex while the T cell zones were located beneath the B cell follicles 
and in the cortex (Figure 3.6, Region B). These locations of the T cell zone and B 
cell follicles locations were similar to WT lymph nodes (Figure 3.6, Regions C 
and D). Finally, some T cells were also observed in the B cell follicles of WT and 
apoE
-/-
 lymph nodes (Figure 3.6, Regions A and C) and these cells are probably 




Figure 3.6 Representative autostitch images of lymph nodes in apoE
-/-
 and WT mice 
demonstrated that hypertrophic lymph nodes did not exhibit disruptions in the general 
organization of the lymph node microenvironment. The shadows in both microscope 
pictures were due to the automatic merging (15% overlap) of adjacent fields during 
autostitch. TCR-β and B220 were used as markers for T and B cells respectively. (Regions A, B, 
C and D) The B cell follicles and T cell zone were located in the same region of the lymph node 
for WT and apoE
-/-
 mice. Hence, there was no disruption in lymph node general organization.  
n = 4 for both groups and the scale bar represents 500µm.  
66 
 
Therefore, hypertrophic lymph nodes did not display disruptions in the 
general organization of the lymph node microenvironment; T and B cells were 
able to migrate to their respective compartments, both lymphocyte compartments 
were in their respective locations, and helper T cells were likely able to migrate 
from the T cell zone into the B cell follicle to provide T cell help. 
 
3.3 Mechanisms of lymph node hypertrophy  
Having characterized the properties of hypertrophic skin draining lymph 
nodes in apoE
-/-
 mice, we sought to determine the mechanisms that mediate the 
formation of these hypertrophic lymph nodes. Lymph nodes may become 
hypertrophic via 3 different mechanisms, namely: increased proliferation of 
lymphocytes within the lymph node, increased lymphocyte entry into the organ 
and finally, impaired lymphocyte egress from the hypertrophic lymph node. These 
3 mechanisms may not be mutually exclusive to each other and thus, we 





3.3.1 Hypertrophic lymph nodes do not exhibit an increase in lymphocyte 
proliferation within the organ  
Lymph nodes in apoE
-/-
 mice may become hypertrophic as a consequence of 
an increase in the proliferation of lymph node resident T and B cells. This is 
because T and B cells constitute a major percentage of the total lymph node 
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cellularity; therefore, an increase in T and B cell proliferation within the lymph 
node will in turn, lead to higher lymphocyte cell counts and the formation of 
hypertrophic lymph nodes. Hence, we investigated the proliferation of T and B 
cells in lymph nodes of WT and apoE
-/-
 mice by immunofluorescence 
microscopy. ApoE
-/-
 and WT lymph node sections were stained with anti TCR-β 
or B220, anti Lyve-1 and anti Ki67 antibody for this analysis. 
 
 
Figure 3.7A Hypertrophy of lymph nodes in apoE
-/-
 mice is not associated with an increase in 
the proliferation of lymph node resident T cells. Ki67 is a protein marker for cells that are 
undergoing proliferation and thus, it allows the identification of proliferating T cells within the 
lymph node. Looking at the T cell zone (region enclosed within the orange box) of WT and apoE
-/-
 
lymph node sections, the images demonstrated that the number of proliferating T cells was similar 
between WT and apoE
-/-
 mice. Hence, lymph node hypertrophy was not mediated by increased T 
cell proliferation. n=4 for both groups and the scale bar represents 100µm.     
 
Ki67 is a protein that serves as a marker for cell proliferation due to its 
exclusive expression in cells that have entered the active phases of the cell cycle 
(Scholzen and Gerdes, 2000). Thus, Ki67, TCR-β and B220 staining of lymph 
node sections allows us to analyze T and B cell proliferation by 
immunofluorescence microscopy. Staining for T cells and Ki67 revealed that the 
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number of proliferating T cells within the T cell zone did not differ between WT 
and apoE
-/-
 mice (Figure 3.7A).  
 
 
Figure 3.7B Hypertrophy of lymph nodes in apoE
-/-
 mice is also not associated with an 
increase in the proliferation of lymph node resident B cells. Ki67 staining for proliferating B 
cells within the B cell follicles (region enclosed in the orange box) revealed that the number of 
proliferating B cells in apoE
-/-
 was higher. However, this difference was not significant because 
these proliferating B cells comprise a small fraction of the vastly expanded B cell population of 
the hypertrophic lymph node. n=5 for both groups and the scale bar represents 100µm.     
 
Co-staining of B cells with Ki67 in WT and apoE
-/-
 lymph nodes revealed that 
the number of proliferating B cells within B cell follicles was higher for 
hypertrophic lymph nodes of apoE
-/-
 mice (Figure 3.7B). However, we felt that 
this was not a significant increase over WT lymph nodes because: i. proliferating 
B cells only comprise a small fraction of the lymph node B cell population and 
this was demonstrated in other B cell follicles of the same lymph node section 
where proliferating B cells were not present in significant numbers (Figure 3.7C) 
ii. the increase in proliferating B cells may be due to a general increase in B cells 
within hypertrophic lymph nodes instead (Figure 3.3B). 
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In conclusion, T and B cell proliferation within the hypertrophic lymph node 
of apoE
-/-
 mice was not significantly increased over WT mice. Hence, lymph node 
hypertrophy in apoE
-/-
 mice is unlikely due to an increase in lymphocyte 
proliferation. 
  
Figure 3.7C Proliferating B cells comprise a small fraction of the total B cell population in 
hypertrophic lymph nodes of apoE
-/-
 mice. Other B cell follicles within the same lymph node 
section (region enclosed in the orange box) did not possess significant numbers of Ki67
+
 B cells. 
Hence, proliferating B cells comprise only a small fraction of the total B cell population in 
hypertrophic lymph nodes of apoE
-/-
 mice. n=5 and the scale bar represents 100µm.     
 
3.3.2 The formation of hypertrophic lymph nodes is not associated with an 
increase in lymphocyte entry into the organ  
Hypertrophic lymph nodes may also develop in apoE
-/-
 mice through an 
increase in lymphocyte entry into the organ, and which may be due to changes in 
the lymph node microenvironment and/or intrinsic changes to the lymphocytes 
themselves.  
The lymph node microenvironment is able to increase the rate of lymphocyte 
entry into the organ through a remodeling of the lymph node entry apparatus such 
as an expansion of the HEV and afferent lymphatic vessel network (Anderson et 
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al., 1975; Webster et al., 2006), higher rate of blood flow towards the lymph node 
(Soderberg et al., 2005), and increased expression of chemokines such as CCL21 
and ICAM-1 by HEV endothelial cells for presentation to lymphocytes (Chen et 
al., 2006).  
Lymphocytes of apoE
-/-
 mice can also mediate lymph node hypertrophy 
through, aberrations that enhance their entry into the lymph nodes. Intrinsic 
changes in lymphocytes which increased entry into the lymph node may include 
increased surface expression of receptors for chemokines that promote lymph 
node entry such as CCR7 which is a receptor for the chemokine CCL21. 
Therefore, 2 different short term adoptive transfer assays were done to determine 
whether lymph node hypertrophy in apoE
-/-
 mice is associated with increased 
entry of lymphocytes into the organ, and to identify the mediator(s) behind 
increased entry.  
We began with the short term adoptive transfer of 20 million donor WT 
CD45.1 lymphocytes and splenocytes into recipient WT and apoE
-/-
 CD45.2 mice 
to test whether the hypertrophic lymph node environment may affect the entry of 
WT donor cells. The donor cells were obtained from 6-10 weeks old WT CD45.1 
mice while the recipient mice were 22-28 weeks old recipient WT and apoE
-/-
 
CD45.2 mice.  
All apoE
-/-
 and WT recipient mice were euthanized 2.5 hours after adoptive 
transfer when there was maximum entry of donor cells into the recipient lymph 
node, and the number of donor cells present within recipient brachial lymph nodes 
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was compared between WT and apoE
-/-
 recipient mice. WT total donor cells were 
gated as CD45.1
+






 and donor B 






 for flow cytometry (Figure 3.8A). 
  
Figure 3.8 Hypertrophic lymph nodes are not mediated by increased lymphocyte entry into 
the lymph node via the lymph node microenvironment. (A) Representative gating strategy for 
the transfer of WT CD45.1 donor cells into WT and apoE
-/-
 CD45.2 recipients. (B) WT and apoE
-/-
 
mice did not display a significant difference in the number of WT CD45.1 donor cells and donor T 
cells present within the brachial lymph nodes after 2.5 hours (p=0.1047 and 0.6559 respectively). 
However, a significantly higher number of WT CD45.1 donor B (*p = 0.0484) cells were present 
in apoE
-/-
 recipient lymph nodes. n=7 for apoE
-/-
 and n= 6 for WT; *p<0.05. 
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The results demonstrated that there was no significant difference for the 
number of total WT donor cells present in brachial lymph nodes of WT mice 
(20232 ± 3278, n=6) and apoE
-/-
 CD45.2 recipient mice (29415 ± 3891, n=7) after 
2.5 hours. The same was also observed for the WT donor T cells where no 
significant difference was observed for the number of WT donor T cells present in 
brachial lymph nodes of WT mice (17801 ± 2905, n=6) and  apoE
-/-
 recipient 
mice (19847 ± 3295, n=7). Finally, apoE
-/-
 recipient mice (2438 ± 612, n=7) 
demonstrated a significant increase over WT recipient mice (889 ± 228, n=6) in 
the number of WT donor B cells present within brachial lymph nodes (Figure 
3.8B).  
Although donor B cells were significantly increased in brachial lymph nodes 
of apoE
-/-
 recipients, there was no significant difference between apoE
-/-
 and WT 
recipients for the total donor cells and donor T cells. Hence, it seems that the 
lymph node microenvironment of apoE
-/-
 mice does not mediate lymph node 
hypertrophy through an increase in lymphocyte entry into the organ.  
Next, we tested whether intrinsic changes in lymphocytes from apoE
-/-
 mice 
may lead to an increase in lymphocyte entry into the lymph node and thus support 
lymph node hypertrophy. Hence, a reverse short term adoptive transfer assay was 
done where 20 million WT CD45.1 and apoE
-/-
 CD45.2 donor lymphocytes, and 
splenocytes were cotransferred at equal proportions (1:1 ratio) into WT CD45.2 
recipients. The recipients were 6 weeks old WT mice while donor cells were 
obtained from 22-28 weeks old WT and apoE
-/-
 mice.  
73 
 
All donor cells were labeled with CFSE, and WT recipients were euthanized 
2.5 hours after adoptive transfer to quantify WT and apoE
-/-
 donor T and B cells 
via flow cytometry. Therefore, donor cells were gated in this manner: 
1. WT donor cells were gated as CFSE+ CD45.1+ and apoE-/- donor cells 




 (Figure 3.9A and B). The number of  
apoE
-/-
 and WT total donor cells in each recipient mouse was calculated 
from the average percentage of total donor cells present in the T and B cell 
tube. 
2. WT donor B cells were gated as CFSE+ CD45.1+ B220+ FSC while apoE-/- 






 FSC (Figure 3.9B and 
C). 
3. WT donor T cells were gated as CFSE+ CD45.1+ CD3+ FSC and apoE-/- 






 FSC (Figure 3.9 B and 
D). 
4. Finally, WT and apoE-/- donor T cell were gated for CCR7 surface 
expression as FSC CCR7
+
 and expressed as a histogram plot for WT and   
apoE
-/-




Figure 3.9 A, B, C, D and E Representative gating strategy for reverse adoptive transfer of 
WT and apoE
-/-











 (C, D) Each WT recipient sample 
was divided into 2 tubes for separate staining of T, B cells. Therefore, within the apoE
-/- 
CD45.2 
and WT CD45.1 donor groups, donor B cells were gated as B220
+
 FSC while donor T cells were 
gated as CD3
+
 FSC.  WT or apoE
-/-
 total donor cells were calculated from the average percentage 
of total donor cells present in both the T and B cell tube. (E) WT and apoE
-/-
 donor T cells in each 
WT recipient sample were gated as FSC CCR7
+
 for CCR7 surface expression, and the results were 





Figure 3.9F Hypertrophic lymph nodes are not mediated by increased apoE
-/-
 lymphocyte 
entry into the organ. In addition, reduced entry of apoE
-/-
 donor T cells into WT recipient 
lymph nodes may be mediated in part by reduced CCR7 surface expression on apoE
-/-
 donor 
T cells.  (Fi) No significant difference was observed in the number of WT and apoE
-/-
 donor B 
cells present in recipient lymph nodes after 2.5 hours (p=0.1769). However, the number of apoE
-/-
 
donor T cells and apoE
-/-
 total donor cells present in recipient lymph nodes after 2.5 hours were 
significantly lesser than WT (*p=0.001 and *p=0.0010 respectively). Hence, apoE
-/-
 lymphocytes 
did not mediate lymph node hypertrophy through increased entry into the lymph node. (Fii)  
ApoE
-/-
 donor T cells demonstrated a reduced surface expression of CCR7 as compared to WT 
donor T cells. Hence, the CCR7 surface expression results suggest that reduced entry of apoE
-/-
 
donor T cells into recipient lymph nodes may be mediated in part by reduced CCR7 surface 
expression. 
n=9 for both groups; *p<0.05. The histogram plot is representative of all samples, and the isotype 
control was pooled from apoE
-/-
 and WT donor T cells. 
76 
 
The results demonstrated that there was no significant difference in donor B 
cells between apoE
-/-
 (701 ± 86, n=9) and WT (916 ± 126, n=9). However, the 
number of apoE
-/-
 donor T cells (4822 ± 1126, n=9) in recipient lymph nodes were 
significantly lesser than WT donor T cells (13770 ± 1930, n=9). The same was 
also observed for total donor cells as well, apoE
-/-
 total donor cells (5614 ± 1247, 
n=9) were significantly lesser than WT total donor cells (13990 ± 1665, n=9) in 
recipient lymph nodes (Figure 3.9Fi). Therefore, the lymph node hypertrophy in 
apoE
-/-
 mice is not accompanied by an enhanced capacity of lymphocytes to enter 
into the lymph node.  
In addition, flow cytometry analysis of WT and apoE
-/-
 donor T cell surface 
CCR7 surface expression demonstrated that apoE
-/-
 donor T cell CCR7 surface 
expression was reduced as compared to WT donor T cells (Figure 3.9Fii). This 
was shown by a shift in the apoE
-/-
 CCR7 curve away from WT mice, and towards 
the isotype control. Thus, the results also suggest that reduced entry of apoE
-/-
 
donor T cells into WT recipient lymph nodes may be mediated in part, by reduced 
CCR7 surface expression on apoE
-/-
 donor T cells. 
In conclusion, the overall lymph node hypertrophy in apoE
-/-
 mice is unlikely 
mediated by an increase in lymphocyte entry into the lymph node. However, the 
increased number of B cells in hypertrophic lymph nodes may be mediated by 






3.3.3 Lymph node hypertrophy is accompanied with reduced lymphocyte 
counts in efferent lymph of apoE
-/-
 mice   
Finally, lymph node hypertrophy in apoE
-/-
 mice may be mediated by 
impaired lymphocyte egress from the organ. Therefore, we conducted a 
preliminary experiment to determine if impaired lymphocyte egress may occur in 
hypertrophic lymph nodes.  
Flow cytometry quantification of lymphocytes within the efferent lymph of 
apoE
-/-
 and WT mice was done in this preliminary experiment. The efferent lymph 
was canulated from the cysterna chyli of all mice as previously described 
(Matloubian et al., 2004) which contains lymphocytes that have egressed from the 
lymph nodes. Hence, a significant reduction in lymphocyte amount within apoE
-/-
 
lymph would suggest the possibility of impaired cellular egress from the 
hypertrophic lymph nodes.     
Lymphocytes were gated as CD45
+













 for flow cytometry of the efferent 







Figure 3.10 Efferent lymph of apoE
-/-
 mice possess a reduction in lymphocyte concentration 
as compared to WT mice. (A) Representative gating strategy for lymphocytes present in the 
efferent lymph. All lymphocytes were gated as CD45
+













. (B) A significant reduction was observed in the 
total lymphocyte concentration (*p=0.0310) and T cell concentration (*p=0.0024) of efferent 
lymph in apoE
-/-
 mice. The B cell concentration was also reduced in apoE
-/-
 mice but the difference 




The results demonstrated that there was a significant reduction in the total 
lymphocyte number of efferent lymph in apoE
-/-
 mice (20590 ± 6806, n=7) as 
compared to WT mice (44620 ± 7094, n=7). A significant reduction was also 
observed in the efferent lymph T cell number of apoE
-/-
 mice (7570 ± 1804, n=7) 
as compared to WT mice (26420 ± 4575, n=7). Finally, the B cell number in 
efferent lymph of apoE
-/-
 mice (8622 ± 2911, n=7) was also lower than WT mice 
(18200 ± 3445, n=7) but this reduction was not significant (Figure 3.10B).  
Hence, the results demonstrate that lymphocyte numbers were generally 
reduced in the efferent lymph of apoE
-/-
 mice and suggest that lymphocyte egress 
from the lymph node may be impaired in these mice.    
 
3.3.4 Lymph node hypertrophy in apoE
-/-
 mice is mediated by impaired 
lymphocyte egress, and this impaired egress is supported by the 
microenvironment of the hypertrophic lymph node   
Impaired lymphocyte egress from the hypertrophic lymph nodes of apoE
-/-
 
mice may be induced by 2 factors; the lymph node microenvironment and 
intrinsic changes in lymphocytes from apoE
-/-
 mice. To test this, 2 different long 





In the first long term adoptive transfer assay, 20 million WT CD45.1 donor 
cells from 6-10 weeks old WT CD45.1 mice were adoptively transferred into 22-
28 weeks old CD45.2 WT and apoE
-/-
 recipient mice at T= -24 hours. The 
recipient mice were then rested overnight to allow equilibration of the transferred 
donor cells (Figure 3.11A). The next day at T= 0 hours, half of the WT and  
apoE
-/-
 recipient mice were euthanized (T0 mice) and the numbers of total donor 
cells, donor T and B cell present within the brachial lymph nodes were quantified 
to calculate the T0 average values (demonstrated in Figure 3.11B).  
At the same time, the remaining WT and apoE
-/-
 recipient mice (T20 mice) 
were injected with 200µg of α-CD62L antibody to prevent further entry of cells 
into the brachial lymph nodes. These recipient mice were euthanized at 20 hours 
post injection when maximum egress of cells has occurred (T= 20 hours). The 
number of total donor cells, donor T and B cells left in the brachial lymph nodes 
were also quantified for all mice, and used to calculate the egress index 
(demonstrated in Figure 3.11B).  
Therefore, this experiment will allow us to determine whether lymph node 
hypertrophy in apoE
-/-
 mice is mediated by impaired lymphocyte egress, and the 






    
Figure 3.11 A and B A summary of the long term adoptive transfer, and an illustration on 
how the egress index is calculated. (A) Scheme for long term adoptive transfer of CD45.1 WT 
donor cells into CD45.2 WT and apoE
-/-
 recipient mice. (B) An illustration on how the egress 
index is calculated. The cell counts, and recipient mice are for illustrative purposes only and do 
not reflect actual experimental values. A larger egress index value (≈1) indicates impaired egress 




Figure 3.11 C and D Lymph node hypertrophy in apoE
-/-
 mice is mediated by impaired 
egress of lymphocytes from the organ, and the lymph node microenvironment supports this 
impairment of egress. (C) Representative gating strategy for the adoptive transfer of WT donor 
cells into apoE
-/-
 and WT recipients. WT total donor cells were gated as CD45.1
+
, WT donor T 













 (D) The egress index of total donor cells, donor T cells and donor B cells were significantly 
increased in apoE
-/-
 recipient mice over WT (*p=0.0003, *p=0.0003, *p=0.0014 respectively). 
Hence, lymph node hypertrophy is mediated by impaired lymphocyte egress, and this was 
supported by the lymph node microenvironment. n=10 for WT, n=8 for apoE
-/-
; *p<0.05   
 
The egress index of various donor cells was calculated for each T20 WT and 
apoE
-/-
 recipient mouse by dividing the T= 20 hours donor cell count against the 
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average of the T= 0 hours donor cell count [T20 cell count / T0 Average]. The 
derivation and calculation of the egress index is illustrated in Figure 3.11B. 
Therefore, the egress index of a cell measures its egress because it compares the 
number of cells left in the lymph node after maximum egress against its average 
initial number. Hence, a larger egress index value (≈1) indicates impaired egress 
in the donor cell of interest while a smaller egress index value (≈0) indicates 
egress.  
Total WT donor cells were gated as CD45.1
+














for flow cytometry (Figure 3.11C). The results demonstrated that the egress 
index was significantly higher for all 3 donor cell types in apoE
-/-
 recipient mice 
as compared to WT (Figure 3.11D). 
The egress index for total donor cells was significantly higher in apoE
-/-
 (1.03 
± 0.20, n=8) as compared to WT mice (0.19 ± 0.03, n=10). The egress index for 
donor T cells was also significantly higher in apoE
-/-
 (1.08 ± 0.22, n=8) as 
compared to WT mice (0.16 ± 0.03, n=10). Finally, the donor B cell egress index 
for apoE
-/-
 mice (1.04 ± 0.21, n=8) was significantly increased over WT mice 
(0.26 ± 0.07, n=10) as well. 
These results demonstrated that WT T and B lymphocytes exhibit impaired 
egress from hypertrophic lymph nodes of recipient apoE
-/-
 mice. Hence, lymph 
node hypertrophy in apoE
-/-
 mice can be mediated by impaired egress of 
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lymphocytes from the lymph node, and the lymph node microenvironment 
supports this impaired egress. 
 
3.3.5 Lymphocytes from apoE
-/-
 mice do not exhibit intrinsic defects that 
prevent their egress from hypertrophic lymph nodes   
Lymphocytes in apoE
-/-
 mice may also mediate lymph node hypertrophy by 
exhibiting intrinsic defects that impair their egress from hypertrophic lymph 
nodes such as the downregulation of S1P receptors. Hence, a reverse long term 
adoptive transfer assay was also done to test whether apoE
-/-
 lymphocytes show 
impaired egress from the lymph nodes.  
The reverse long term adoptive transfer assay is identical to the long term 
adoptive transfer assay shown in Section 3.3.4 except for 2 differences: i. 20 
million WT CD45.1 and apoE
-/-
 CD45.2 donor cells were cotransferred at equal 
proportions (1:1 ratio) into 6 weeks old WT CD45.2 recipient mice, ii. the donor 
mice were 22-28 weeks old WT CD45.1 as well as apoE
-/-
 CD45.2 mice and iii. 
donor mice of the T= 20 hours group were injected with 100µg of α-CD62L 
antibody instead. 
Donor cells were gated in this manner for the reverse long term adoptive 
transfer: 
1. WT donor cells were gated as CFSE+ CD45.1+ and apoE-/- donor cells 




(Figure 3.12A, B). 
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2. Within each donor group, donor B cells were gated as B220+ CD3- while 




 (Figure 3.12C). 
 
 
Figure 3.12 A, B and C Representative gating strategy for reverse adoptive transfer of WT 
and apoE
-/-
 donor cells into WT recipients. (A) All donor cells were gated from recipient cells 
as CFSE
+
























Figure 3.12D The egress index of apoE
-/-
 donor cells were not significantly different from 
WT. Therefore, apoE
-/-
 lymphocytes did not possess intrinsic defects that impair egress from 
the lymph node, and egress impairment was supported by the lymph node 
microenvironment alone. (D) The egress index of total donor cells, donor T cells and donor B 
cells were not significantly different between apoE
-/-
 and WT recipient mice (p=0.9485, p=0.9768, 
p=0.7329 respectively). Hence, apoE
-/-
 lymphocytes did not possess intrinsic defects that impair 
egress from the lymph node.  n=8 for both groups; *p<0.05   
 
The results demonstrated that there was no significant difference between the 
egress index of WT donor cells and apoE
-/-
 donor cells (Figure 3.12D). The 
egress index of total donor cells were not significantly different between WT 
(0.23 ± 0.06, n=8) and apoE
-/-
 mice (0.23 ± 0.05, n=8). There was also no 
significant difference in the egress index of donor T cells between WT (0.18 ± 
0.04, n=8) and apoE
-/-
 mice (0.18 ± 0.05, n=8). Finally, the egress index of apoE
-/-
 
donor B cells (0.21 ± 0.08, n=8) was also not significantly different from WT 
donor B cells (0.25 ± 0.09, n=8). Therefore, apoE
-/-
 lymphocytes have no defect in 
their egress capacity and thus, only changes in the lymph node microenvironment 





In conclusion, lymph node hypertrophy in apoE
-/-
 mice is mediated in part, by 
impaired lymphocyte egress from the lymph node, and the lymph node 
microenvironment alone supports this impaired egress. 
 
3.4 The lymph node microenvironment and its support of impaired 
lymphocyte egress  
Having identified the mechanism of lymph node hypertrophy and the 
involvement of the lymph node microenvironment, we determined how changes 
in the lymph node microenvironment induce impaired lymphocyte egress. 
Therefore, we focused on 3 components of the lymph node microenvironment that 
have been involved in lymphocyte egress from the lymph node namely; S1P 
(Matloubian et al., 2004), CCL21 (Pham et al., 2008) and lymphatic vessels 
(Mandala et al., 2002). 
 
3.4.1 Changes in S1P levels in the lymph node microenvironment may 
account for impaired lymphocyte egress  
Lymphocyte egress from the lymph node is mediated by the interaction 
between the lipid S1P as well as its receptor on the lymphocyte surface, S1P1 
(Mandala et al., 2002; Matloubian et al., 2004), and this interaction mediates 
egress by overcoming the retention signal of CCL21 (Pham et al., 2008). In 
addition, S1P mediated egress occurs along a S1P concentration gradient between 
the blood, lymph and lymph node (Pappu et al., 2007) with S1P concentration 
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highest in blood, intermediate in the lymph and lowest in the lymph node. Any 
disruption in this concentration gradient blocks lymphocyte egress from the 
lymph node (Pappu et al., 2007; Schwab et al., 2005). 
Therefore, we asked whether S1P levels in lymph, blood and lymph node may 
be altered in apoE
-/-
 mice. S1P levels were determined through mass spectrometry 
measurement of S1P levels in the lymph node, efferent lymph and plasma of 22-




Figure 3.13 Mass spectrometry measurements of S1P levels in efferent lymph, lymph node 
and plasma revealed changes in S1P levels within all 3 compartments. (A) Mass spectrometry 
measurements demonstrated that S1P levels were significantly reduced (*p=0.0138) in the efferent 
lymph of apoE
-/-
 mice. (B) S1P levels in lymph nodes were also reduced in apoE
-/-
 mice as 
compared to WT mice. However, the reduction was not significant (p=0.0701). (C) Finally, in 
contrast to the efferent lymph and lymph nodes, S1P levels in plasma were significantly higher 
(*p=0.0023) in apoE
-/-
 mice as compared to WT. n=24 for both groups for plasma, n=19 for WT, 
16 for apoE
-/-
 for lymph nodes and n=7 for both groups for efferent lymph; *p<0.05    
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The mass spectrometry results demonstrated that S1P levels were generally 
altered in the blood, efferent lymph and lymph nodes of apoE
-/-
 mice (Figure 
3.13). S1P levels were reduced in the hypertrophic lymph nodes of apoE
-/-
 mice 
(1.9 ± 0.75 µM, n=16) but this reduction was not statistically different from WT 
(4.25 ± 0.96 µM, n=19). S1P levels in the efferent lymph were significantly 
reduced in apoE
-/-
 mice (0.22 ± 0.03 µM, n=7) as compared to WT mice (0.34 ± 
0.03 µM, n=7). Finally, unlike S1P levels in lymph nodes and efferent lymph, 
S1P levels in the plasma of apoE
-/-
 mice (0.78 ± 0.07 µM, n=24) were 
significantly higher than WT mice (0.53 ± 0.04 µM, n=24).  
Hence, these results suggest that the apoE
-/-
 lymph node microenvironment 
may support impaired egress through a reduction in S1P levels of the efferent 
lymph and lymph node, and a possible disruption of the S1P gradient between the 
efferent lymph and blood.  
Therefore, the lymph node microenvironment of hypertrophic lymph nodes 
likely impaired lymphocyte egress in part through alterations in S1P levels of the 







3.4.2 The lymph node microenvironment may also impair egress through an 
increase in the CCL21 retention signal 
The 1
st
 step of S1P mediated lymphocyte egress from the lymph node occurs 
at the cortical sinus (Cyster and Schwab, 2012), and it involves the migration of 
the lymphocyte from the lymph node stroma into the lumen of the vessel (Cyster 
and Schwab, 2012; Grigorova et al., 2010; Grigorova et al., 2009). This migration 
into the cortical sinus can be blocked by CCL21 which interacts with CCR7 on 
the lymphocyte surface and retains the lymphocyte within the lymph node stroma 
(Pham et al., 2008). Therefore, we ask if the hypertrophic lymph node 
microenvironment also blocked egress through an increase in the CCL21 retention 
signal, and we addressed this question by measuring the total amount of CCL21 
present in the lymph nodes of WT and apoE
-/-
 mice via ELISA. 
 
 
Figure 3.14A CCL21 protein concentration was significantly higher in hypertrophic lymph 
nodes of apoE
-/-
 mice. (A) CCL21 ELISA was done to measure the total CCL21 protein level of 
WT and apoE
-/-
 lymph nodes, and the results were expressed as CCL21 concentration. The CCL21 
concentration was significantly higher (*p=0.0133) in apoE
-/-
 mice as compared to WT mice. 
However, we felt that this increase may not be biologically significant. n=10 for WT, n=6 for 
apoE
-/-
; *p<0.05   
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CCL21 protein levels were expressed as concentration in ng/ml for the ELISA 
assay (Figure 3.14A), and the results demonstrated that the CCL21 protein 
concentration was significantly higher in lymph nodes of apoE
-/-
 mice (70.61 ± 
5.31 ng/ml, n=6) as compared to WT mice (57.81 ± 1.58 ng/ml, n=10). Although 
the lymph node CCL21 protein concentration was significantly higher in apoE
-/-
 
mice, we felt that the difference may not be biologically significant. Thus, we 
further investigated the possibility of differences in CCL21 distribution by 
immunofluorescence microscopy where we focused on local CCL21 protein 
expression at cortical sinuses in lymph nodes of WT and apoE
-/-
 mice. 
Our immunofluorescence microscopy data (Figure 3.14B) demonstrated that 
CCL21 localized close to the cortical sinuses of WT and apoE
-/-
 lymph nodes but, 
was more abundant on cortical sinuses in lymph nodes from apoE
-/-
 mice. This 
increase in apoE
-/-
 mice is shown in Figures 3.14Bi, ii, and iii (yellow arrows).  
In addition, some WT cortical sinuses (indicated by orange arrows) in Figure 
3.14Biii displayed a very weak or negative CCL21 signal when acquired with the 
same exposure as that used for apoE
-/-
 sections. This demonstrates that local 
CCL21 levels were indeed lower at the WT cortical sinuses, and further supports 
the finding that apoE
-/-
 cortical sinuses feature higher local CCL21 expression 





Figure 3.14B CCL21 local expression was increased on cortical sinuses of the hypertrophic 
lymph node. (i, ii, iii) CCL21 localized close to the cortical sinus in WT and apoE
-/-
 lymph nodes. 
However, the expression level of CCL21 at the cortical sinus was generally more abundant in 
apoE
-/-
 hypertrophic lymph nodes (yellow arrows). (iii) Further evidence for higher CCL21 local 
expression in apoE
-/-
 mice was seen in some WT cortical sinuses (orange arrows). In these cortical 
sinuses, CCL21 was present at such low levels that the CCL21 signal was weak or absent when 
the exposure was held constant for WT and apoE
-/-
 sections. This further supports the finding that 
apoE
-/-
 cortical sinus exhibited higher local CCL21 expression than WT mice. 
The position of B cell follicles in the vicinity of cortical sinuses are labeled with a text box and the 
scale bar represents 50µm. Each pair of representative WT and apoE
-/-
 pictures were obtained from 




Figure 3.14C Representative CCL21 isotype control sections for apoE
-/-
 and WT lymph 
nodes demonstrated that the CCL21 staining observed in Figure 3.14B was specific. The 
scale bar represents 50µm.  
 
Therefore, the combined ELISA, and immunofluorescence microscopy results 
suggest that the CCL21 retention signal was stronger within hypertrophic lymph 
nodes of apoE
-/-
 mice. Hence, the hypertrophic lymph node microenvironment 
may also mediate impaired lymphocyte egress through an increase in the CCL21 
retention signal, and this increase in retention might work together with changes 
in S1P levels to mediate impaired lymphocyte egress. 
 
3.4.3 Lymphocyte egress from the lymph node also requires functional 
lymphatic vessels 
Lymphocyte egress from the lymph node is also dependent on the ‘roads’ that 
these cells use to exit the organ: the lymphatic vessels (Tan et al., 2012). The 
importance of functional lymphatic vessels in lymphocyte egress is demonstrated 
by the cortical sinus; the presence of fluid flow, and its continued maintenance in 
these vessels transports lymphocytes downstream to the medullary sinuses and out 
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of the lymph node via the efferent lymphatic vessels (Grigorova et al., 2010; 
Grigorova et al., 2009). Thus, given the role of the lymphatic vessel in 
lymphocyte egress, we asked if the hypertrophic lymph node exhibit changes in 
lymphatic vessel that may contribute to impaired lymphocyte egress from the 
organ. 
 
3.4.4 Hypertrophic lymph nodes from apoE
-/-
 mice displayed an expansion of 
the lymphatic vessel network  
We first examined the lymph nodes of apoE
-/-
 and WT by 
immunofluorescence microscopy to study the overall lymphatic vessel network. 
 
 
Figure 3.15A Autostitch images demonstrated that hypertrophic lymph nodes in apoE
-/-
 mice 
displayed an expansion of the lymphatic vessel network, and this was not observed in WT 
lymph nodes. ApoE
-/-
 lymphatic vessels covered a greater area of the lymph node than WT, and 
the lymphatic vessels were seen projecting into the lymph node cortex as well. These results 
suggest an expansion of the lymphatic vessel network inside hypertrophic lymph nodes of apoE
-/-
 




Our immunofluorescence microscopy results showed that the lymphatic vessel 
network of hypertrophic lymph nodes in apoE
-/-
 mice covered a larger area of the 
lymph node as compared to WT mice. In addition, apoE
-/-
 lymphatic vessels were 
seen projecting into the lymph node cortex whereas this was not observed for WT 
lymphatic vessels (Figure 3.15A). Hence, our results suggested that there was an 
abnormal expansion of lymphatic vessels in hypertrophic lymph nodes of apoE
-/-
 
mice. Therefore, flow cytometry quantification of LECs in WT and apoE
-/-
 lymph 
nodes was subsequently done to validate this observation. 
 
 
Figure 3.15B and C Flow cytometry quantification of LECs demonstrated the expansion of 
the lymphatic vessel network within hypertrophic lymph nodes of apoE
-/-
 mice. (B) LECs 






. (C) LECs were significantly increased (*p=0.045) in 
hypertrophic lymph nodes of apoE
-/-
 mice over WT. n=8 for WT, n=10 for apoE
-/-
; *p<0.05   
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 for flow cytometry 
(Figure 3.15B). Our data (Figure 3.15C) demonstrated that the number of LECs 
was significantly increased in hypertrophic lymph nodes of   apoE
-/-
 mice (7528 ± 
2951, n=10) over WT mice (303 ± 148, n=8). Since LECs make up the lymphatic 
vessels, this flow cytometry results further demonstrated the expansion of the 
lymphatic vessel network within hypertrophic lymph nodes of apoE
-/-
 mice.  
Therefore, hypertrophic lymph nodes from apoE
-/-
 mice displayed an 
expansion of the lymphatic vessel network.  
 
3.4.5 Lymphatic vessels in hypertrophic lymph nodes also display abnormal 
vessel morphology in the form of dilated vessels. 
Having demonstrated an expansion of the lymphatic vessel network within 
hypertrophic lymph nodes, we asked if these lymphatic vessels also exhibit 
abnormal vessel morphology. By using immunofluorescence microscopy for this 
study, we focused on the morphology of cortical as well as medullary lymphatic 
vessels in lymph nodes of WT and apoE
-/-
 mice as they are both exit routes for 
lymphocytes. Our immunofluorescence microscopy results (Figure 3.16A) 
showed that cortical and medullary lymphatic vessels in hypertrophic lymph 
nodes of apoE
-/-





Figure 3.16A Immunofluorescence microscopy revealed that lymphatic vessels within 
hypertrophic lymph nodes displayed abnormal vessel morphology in the form of vessel 
dilation. Immunofluorescence microscopy showed that cortical and medullary lymphatic vessels 
in hypertrophic lymph nodes were dilated. The scale bar represents 100µm. n=4 for both groups.  
 
Thus, we proceed to verify this observation by quantifying the area of cortical 
and medullary lymphatic vessels in WT and apoE
-/-
 lymph nodes. All lymphatic 
vessel areas were quantified using the outline function of the Axiovision program 
(Version 4.8; Carl Zeiss Micro Imaging, Inc.) with dilated lymphatic vessels 





Figure 3.16B Cortical and medullary lymphatic vessels within hypertrophic lymph nodes of 
apoE
-/-
 mice were dilated as compared to WT mice. Quantification of the lymphatic vessel area 
showed that apoE
-/-
 cortical and medullary vessels exhibited a significant increase in vessel area 
(*p<0.001 for both). This demonstrates the presence of dilated lymphatic vessels in hypertrophic 
lymph nodes. n=4 for both groups; *p<0.05 
 
Our results (Figure 3.16B) showed that the mean cortical lymphatic vessel 
area was significantly higher in apoE
-/-
 lymph nodes (6187 ± 327.8 µm
2
, n=4) as 
compared to WT mice (467.7 ± 58.57 µm
2
, n=4). The same trend was also 
observed in the medullary lymphatic vessels; apoE
-/-
 lymph nodes (6023 ± 256.7 
µm
2
, n=4) exhibited a significant increase in the mean medullary lymphatic vessel 
area over WT mice (406.8 ± 74.42 µm
2
, n=4). Therefore, lymphatic vessels in 
hypertrophic lymph nodes of apoE
-/-
 mice showed abnormal vessel morphology in 








 mice exhibit leaky (or dysfunctional) efferent lymphatic vessels 
Having established the presence of an expanded lymphatic vessel network and 
dilated lymphatic vessels in apoE
-/-
 mice, we asked if these mice also exhibit 
perturbations in efferent lymphatic transport. Hence, we conducted 
lymphangiography experiments where the transport of Evans Blue dye from the 
footpad to the proximal draining lymph nodes and finally, to the efferent 
lymphatic vessels was observed and analyzed (Figure 3.17A).   
The lymphangiography results (Figure 3.17B) demonstrated that Evans Blue 
dye leaked out from the apoE
-/-
 efferent lymphatic vessels downstream of the iliac 
lymph node into the surrounding tissue, and this was not observed in WT efferent 
lymphatic vessels (red arrows). In addition, apoE
-/-
 efferent lymphatic vessels 
occasionally displayed an enlargement in certain regions of the lymphatic vessel 
(orange arrows) and this was also not seen in WT (Figure 3.17C). Together, these 
results suggest that efferent lymphatic vessels in apoE
-/-











Figure 3.17 Efferent lymphatic vessels were likely to be dysfunctional in apoE
-/-
 mice. The 
direction of lymph flow is indicated by the black arrows on the left. (A) Route of transport for 
Evans Blue dye upon injection into the rear footpad. The dye is transported in afferent and efferent 
lymphatic vessels through the popliteal as well as iliac lymph nodes and finally, to the cysterna 
chyli where it returns back to the blood circulation (B) Lymphangiography experiments 
demonstrated that in apoE
-/-
 mice, Evans Blue dye leaked out from the efferent lymphatic vessels 
downstream of the iliac lymph node and into the surrounding tissue. This dye leakage was not 
observed in the efferent lymphatic vessels of WT mice. (C) Enlarged regions along the efferent 
lymphatic vessels were also occasionally observed in apoE
-/-
 mice but not in WT mice, and this 
enlargement was likely to be formed by fluid accumulation within the vessel. Together, these 






In conclusion, the aberrant dilation and expansion of lymphatics within lymph 
nodes of apoE
-/-
 mice, and the possible disruption in lymphatic flow suggest that 
lymphatic vessels in hypertrophic lymph nodes were likely to be dysfunctional. 
Therefore, the hypertrophic lymph node microenvironment may also impair 
lymphocyte egress through the presence of dysfunctional lymphatic vessels inside 
the lymph node. 
 
3.5 Hypercholesterolemia in apoE
-/-
 mice contributes to lymph node 
hypertrophy  
Since hypertrophic lymph nodes may contribute to impaired immunity in 
apoE
-/-
 mice, we asked whether lymph node hypertrophy may be therapeutically 
treated to fully reverse hypertrophy or reduce its severity. Therefore, we treated 
apoE
-/-
 mice with Ezetimibe, a cholesterol lowering drug which works by 
inhibiting the uptake of dietary cholesterol from intestines (Rosenblum et al., 
1998; van Heek et al., 2001; Van Heek et al., 1997), and determined its effects on 
the hypertrophic lymph nodes. We chose this strategy of treatment because lymph 
node hypertrophy is associated with atherosclerosis as well as 
hypercholesterolemia, and previous studies have shown that Ezetimibe treatment 
reduces hypercholesterolemia and atherosclerosis in apoE
-/-
 mice (Rosenblum et 





3.5.1 Ezetimibe treatment ameliorates lymph node hypertrophy in apoE
-/-
 
mice through a general restoration of cellular egress 
Since hypertrophic lymph nodes of apoE
-/-
 mice exhibited a significantly 
increased lymph node cellularity, T and B cell counts, we determined whether 
Ezetimibe treatment in apoE
-/-
 mice ameliorates lymph node hypertrophy through 
a reduction in lymph node cellularity, T and B cells counts within the lymph node. 
 
 
Figure 3.18A Ezetimibe treatment in apoE
-/-
 mice significantly reduced lymph node 
cellularity, T and B cell counts. Quantification of lymph node cellularity, T and B cell counts in 









NT) revealed a significant reduction in lymph node cellularity (*p<0.0001), T cell (*p=0.0004) 
and B cell counts (*p< 0.0001). Lymph node cellularity was quantified with a haemocytometer 
while T and B cell counts were quantified via flow cytometry; *p<0.05  
Results were expressed as fold increase in apoE
-/-
 over WT, and the data was pooled from 2 
independent experiments with 4-6 mice per group in each experiment. A representative Ezetimibe 




 mice demonstrated a significant reduction in lymph 





 mice (3.17 ± 0.35 increase over WT, n=8), and the lymph node 
cellularity of Ezetimibe treated apoE
-/-
 mice was similar to WT lymph nodes with 
a 1.2 fold increase over WT (Figure 3.18A, lymph node cellularity). In addition, 
Ezetimibe treatment in WT mice does not alter lymph node cellularity (data not 
shown).   
The same trend was also observed for lymph node T cells; the lymph node T 
cell count was significantly reduced in Ezetimibe treated apoE
-/-
 mice (1.21 ± 0.12 
fold increase over WT, n=10) as compared to non-treated  apoE
-/-
 mice (2.83 ± 
0.38 fold increase over WT, n=8), and the lymph node T cell counts of Ezetimibe 
treated apoE
-/-
 mice was also similar to WT lymph nodes with a 1.21 fold increase 
over WT (Figure 3.18A, T cells).  
Finally, B cell counts were also significantly reduced in Ezetimibe treated 
apoE
-/-
 mice (1.16 ± 0.12 fold increase over WT, n=10) as compared to non-
treated apoE
-/-
 mice (3.22 ± 0.25 fold increase over WT, n=8), and the B cell 
counts in Ezetimibe treated apoE
-/-
 mice were also similar to WT lymph nodes 
with a 1.16 fold increase over WT (Figure 3.18A, B cells).  
Therefore, our results demonstrated that Ezetimibe treatment in apoE
-/-
 mice 
ameliorated lymph node hypertrophy since apoE
-/-
 lymph node cellularity, T and 
B cell counts were almost similar to WT lymph nodes.  
Because lymph node hypertrophy in apoE
-/-
 mice is mediated by impaired 
lymphocyte egress from the organ, we ask whether the amelioration of lymph 
node hypertrophy by Ezetimibe treatment was due to a restoration of lymphocyte 
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egress from the lymph nodes. Thus, we performed a long term adoptive transfer 
of WT donor cells into WT recipient mice, non-treated and Ezetimibe-treated 
recipient apoE
-/-
 mice, and compared the egress index of WT total donor, donor T 
and B cells in Ezetimibe-treated recipient apoE
-/-
 mice against the other 2 
recipient mice groups. 
 
Figure 3.18B Ezetimibe treatment in apoE
-/-
 mice restores total donor and T cell egress but 
not B cell egress. The egress index of total donor cells in Ezetimibe-treated apoE
-/-
 mice was 
significantly reduced (*p=0.0321) as compared to non-treated apoE
-/-
 mice and was significantly 
increased as compared to WT mice (*p=0.017). The egress index of donor T cells in Ezetimibe 
treated apoE
-/-
 mice was also significantly reduced (*p=0.0125) as compared to non-treated apoE
-/-
 
mice but was not significantly different (p=0.0989) from WT mice. However, the B cell egress 
index of Ezetimibe treated apoE
-/-
 mice was not significantly different (p=0.5940) from non-
treated apoE
-/-
 mice, and was significantly higher (*p=0.0456) than WT mice. Finally, the egress 
index of non-treated apoE
-/-
 mice was significantly higher than WT mice for total donor cells, T 
and B cells (*p<0.001, *p=0.0002 and 0.0019 respectively).    
n=6 for WT recipient mice, n=5 for Ezetimibe treated apoE
-/-
 recipient mice and n=4 for non-
treated apoE
-/-
 recipient mice. The gating of WT donor cells, and calculation of the egress index 




Our long term adoptive transfer results demonstrated that Ezetimibe treatment 
in apoE
-/-
 mice restored T cell and total donor cell egress from the lymph node but 
not B cell egress (Figure 3.18B).  
The egress index of WT total donor cells was significantly reduced in 
Ezetimibe treated apoE
-/-
 mice (0.45 ± 0.09, n=5) as compared to non-treated 
apoE
-/-
 mice (0.78 ± 0.07, n=4), and significantly increased as compared to WT 
mice (0.15 ± 0.04, n=6). In addition, the egress index of total donor cells was 
significantly increased in non-treated apoE
-/-
 mice (0.78 ± 0.07, n=4) as compared 
to WT mice (0.15 ± 0.04, n=6).  
For donor T cells, the egress index of donor T cells in Ezetimibe treated  
apoE
-/-
 mice (0.34 ± 0.11, n=5) was significantly reduced as compared to non-
treated apoE
-/-
 mice (0.95 ± 0.15, n=4) but was not significantly different from 
WT mice (0.14 ± 0.04, n=6) while the egress index of donor T cells was 
significantly increased in non-treated apoE
-/-
 mice (0.95 ± 0.15, n=4) as compared 
to WT mice (0.14 ± 0.04, n=6).  
Finally, the egress index of donor B cells in Ezetimibe treated apoE
-/-
 mice 
(1.12 ± 0.44, n=5) was not significantly different from non-treated apoE
-/-
 mice 
(0.83 ± 0.14, n=4) but was significantly higher than WT mice (0.17 ± 0.08, n=6), 
and the egress index of donor B cells was significantly increased in non-treated 
apoE
-/-
 mice (0.83 ± 0.14, n=4) as compared to WT mice (0.17 ± 0.08, n=6). In 
addition, a longer adoptive transfer in non-treated apoE
-/-
 mice (T24 instead of T20) 
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demonstrated no significant difference in the egress index of WT donor B cells 
between 20 and 24 hours post injection (data not shown). 
 
Therefore, Ezetimibe treatment reduced lymph node cellularity and T cell 
counts in apoE
-/-
 lymph nodes by restoring total cellular and T cell egress. 
However, the reduction in B cell counts by Ezetimibe treatment was not likely to 
be mediated by restored B cell egress because the egress of WT donor B cells in 
non-treated apoE
-/-
 mice at a longer timepoint of T24 was not significantly 
different when compared with T20. Thus, Ezetimibe treatment in apoE
-/-
 mice 
likely reduced lymph node B cell counts through other mechanisms. 
In conclusion, Ezetimibe treatment in apoE
-/-
 mice ameliorates lymph node 
hypertrophy through a general restoration of cellular egress.  
 
3.5.2 Ezetimibe restores cellular egress in part by remodeling of lymphatic 
vessels in apoE
-/-
 lymph nodes 
Because the lymph node microenvironment supports egress impairment, and 
impaired egress was reversed by Ezetimibe, we ask whether Ezetimibe restored 
cellular egress by a restoration of the lymph node microenvironment. Therefore, 
we addressed this question by quantifying the LECs in lymph nodes of WT, 








Figure 3.19A Ezetimibe treatment in apoE
-/-
 mice reduced the size of the lymphatic vessel 
network. (A) Flow cytometry quantification of LECs in lymph nodes of WT, Ezetimibe treated 
and non-treated apoE
-/-
 mice. Ezetimibe treatment in apoE
-/-
 mice resulted in a significant 
reduction (*p<0.0001) in LEC counts as compared to non-treated apoE
-/-
 mice, and was not 
significantly different (p=0.2135) from WT mice while non-treated apoE
-/-
 mice demonstrated a 
significant increase (*p<0.0001) in LEC counts as compared to WT. 
n=8 for WT mice, n=10 for Ezetimibe treated and non-treated apoE
-/-
 mice. Flow cytometry and 
LEC gating was identical to Figure 3.15; *p<0.05 
 
Flow cytometry quantification of LECs (Figure 3.19A) demonstrated that the 
LEC counts of Ezetimibe treated apoE
-/-
 mice (1483 ± 280, n=10) was 
significantly reduced as compared to non-treated apoE
-/-
 mice (9900 ± 1169, 
n=10) but was not significantly different from WT mice (2013 ± 294, n=8) while 
LEC counts of non-treated apoE
-/-
 mice (9900 ± 1169, n=10) was significantly 
higher than and WT mice (2013 ± 294, n=8). Therefore, these results demonstrate 
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that Ezetimibe treatment in apoE
-/-
 mice reduced the size of the lymph node 
lymphatic vessel network.  
We next asked whether Ezetimibe treatment also reduced the dilation of 
lymphatic vessels in hypertrophic lymph nodes of apoE
-/-
 mice. Thus, we also 
quantified the vessel areas of cortical and medullary lymphatic vessels in the 
lymph nodes of WT, Ezetimibe treated and non-treated apoE
-/-
 mice.    
 
Figure 3.19B Ezetimibe treatment in apoE
-/-
 mice reduced the dilation of cortical and 
medullary lymphatic vessels. (Cortex) Non-treated apoE
-/-
 mice exhibited a significant increase 
(*p<0.001 for both) in the average cortical lymphatic vessel area as compared to Ezetimibe-treated 
apoE
-/-
 and WT mice. However, Ezetimibe treatment in apoE
-/-
 mice resulted in a significant 
reduction (*p<0.0001) in the average cortical lymphatic vessel area as compared to non-treated 
apoE
-/-
 mice but, was significantly increased (*p<0.0001) as compared to WT mice. (Medulla) The 
same pattern was also observed for medullary lymphatic vessels, non-treated apoE
-/-
 mice 
exhibited a significant increase in the average cortical lymphatic vessel area as compared to 
Ezetimibe-treated apoE
-/-
 and WT mice (*p<0.001 for both) while Ezetimibe treatment in apoE
-/-
 
mice also significantly reduced (*p<0.0001) the average medullary lymphatic vessel area as 
compared to non-treated apoE
-/-
 mice and remained significantly higher (*p<0.0001) than WT 
mice.   
n=4 for all 3 groups. Calculation of average cortical and medullary lymphatic vessels were 
identical to Figure 3.16; *p<0.05 
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Quantification of the average vessel area in cortical and medullary lymphatic 
vessels also revealed that Ezetimibe treatment in apoE
-/-
 mice reduced the dilation 
of these lymphatic vessels (Figure 3.19B).  
The average cortical lymphatic vessel area of Ezetimibe treated apoE
-/-
 mice 
(2181 ± 92.19 µm
2
, n=4) was significantly reduced as compared to non-treated 
ApoE
-/-
 mice (6187 ± 327.8 µm
2
, n=4) but was significantly higher than the 
average cortical lymphatic vessel area of WT mice (467.7 ± 58.57 µm
2
, n=4) 
while average cortical lymphatic vessel area was significantly increased in non-
treated apoE
-/-
 mice (6187 ± 327.8 µm
2
, n=4) as compared to WT mice (467.7 ± 
58.57 µm
2
, n=4).  
The same trend was also observed for the average medullary lymphatic vessel 
area; Ezetimibe treated apoE
-/-
 mice (1930 ± 141.1 µm
2
, n=4) demonstrated a 
significant reduction in the average medullary lymphatic vessel area as compared 
to non-treated apoE
-/-
 mice (6023 ± 256.7 µm
2
, n=4) but was significantly higher 
than WT mice (406.8 ± 74.42 µm
2
, n=4) while the average medullary lymphatic 
vessel area of non-treated apoE
-/-
 mice (6023 ± 256.7 µm
2
, n=4) was significantly 
higher than WT mice (406.8 ± 74.42 µm
2
, n=4). In addition, immunofluorescence 
microscopy also demonstrated that there was no difference between Ezetimibe-
treated apoE
-/-
 mice and non-treated apoE
-/-
 mice in CCL21 local expression levels 
on cortical sinuses (data not shown).  
Therefore, Ezetimibe treatment in apoE
-/-
 mice reduced the dilation of the 
lymph node lymphatic vessels and together, these flow cytometry and 
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immunofluorescence microscopy results demonstrate that the reversal of 
lymphatic vessel abnormalities is sufficient to restore cellular egress.  
Finally, ongoing mass spectrometry measurements of S1P levels in efferent 
lymph and lymph node of Ezetimibe treated apoE
-/-
 mice suggest that S1P levels 
may be increased in these compartments (data not shown), and work is in progress 
to confirm these observations. Thus, changes in S1P levels may also further 
contribute to the restoration of cellular egress in Ezetimibe treated apoE
-/-
 mice.  
In conclusion, hypertrophic lymph nodes in apoE
-/-
 mice can be ameliorated 
via Ezetimibe treatment, and the amelioration of lymph node hypertrophy likely 













4.1 The hypertrophic lymph node and its contribution to impaired immunity 
in apoE
-/-
 mice  
Lymph nodes contribute to functional host immunity by gathering together 
naïve lymphocytes and antigen laden APCs within the organ thereby increasing 
the probability that a naïve lymphocyte will encounter its cognate antigen, and 
become activated (Junt et al., 2008; von Andrian and Mempel, 2003). Therefore, 
there are 2 likely mechanisms for hypertrophic lymph nodes to contribute to 
impaired immunity in apoE
-/-
 mice; impaired lymphocyte entry into the lymph 
node and impaired lymphocyte egress from the lymph node. 
 
Figure 4.1 The contribution of hypertrophic lymph nodes to impaired immunity in apoE
-/-
 
mice. Hypertrophic lymph nodes may contribute to impaired immunity via 2 mechanisms, and our 
experimental results demonstrate that impaired T and B cell egress from the lymph node is likely 
to be main mechanism, and reduced entry of T cells further contributing to impaired immunity. 
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Our short term adoptive transfer assays demonstrated that the lymph node 
microenvironment from apoE
-/-
 mice does not impair lymphocyte entry into the 
lymph node. However, T cells from apoE
-/-
 mice exhibited a reduced ability to 
enter the lymph node due in part to a likely reduction in CCR7 surface expression, 
and this may contribute to impaired immunity. This is because a reduction in T 
cell entry may subsequently lead to a reduced probability of antigen encounter, 
and T cell activation during an infection. In addition, reduced entry of T cells into 
the lymph node might also lead to reduced CD4 T cell help to B cells for isotype 
switching. Thus, reduced apoE
-/-
 T cell entry into the lymph node may partially 
account for impaired immunity in the mouse.     
In contrast to lymph node entry, our long term adoptive transfer results 
showed that the lymph node microenvironment from apoE
-/-
 mice (or 
hypercholesterolemic mice) impairs both T as well as B cell egress, and egress 
impairment is supported by the lymph node microenvironment alone. Therefore, 
the main contribution of hypertrophic lymph nodes to impaired immunity in  
apoE
-/-
 mice may be via reducing the egress of lymphocytes from the lymph node. 
In addition, both CD4 and CD8 T cells are likely affected by impaired egress 
since the flow cytometry results demonstrate that both cells were present within 
the hypertrophic lymph nodes at similar proportions. 
This impaired egress of lymphocytes from the lymph node may lead to 
impaired immunity through 2 mechanisms: i. if activated CD4 TH1 T cells as well 
as CD8 T cells are unable to exit the lymph node to migrate to their site of action, 
they will not be able to mediate their effector functions such as macrophage 
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stimulation (CD4 TH1 T cells), and induction of apoptosis in infected cells (CD8 
T cells) ii. naïve T and B lymphocytes which fail to encounter their cognate 
antigen in a primary lymph node are unable to leave, and migrate to downstream 
secondary lymph nodes and the blood circulation to continue antigen surveillance 
(von Andrian and Mempel, 2003). The disruption of antigen surveillance likely 
results in reduced activation of T and B cells during infection as a result of poor 
antigen sampling.  
In addition to impaired lymphocyte egress and reduced T cell entry into the 
lymph node, our lab showed previously that apoE
-/-
 mice also exhibit impaired 
skin DC migration from the periphery to the lymph node (Angeli et al., 2004). 
Therefore, impaired DC entry might lead to reduced antigen presentation to naïve 
lymphocytes within the lymph node, and reduced activation of these naïve 
lymphocytes. All these mechanisms may thus contribute to impaired immunity in 
apoE
-/-
 mice.   
In conclusion, the main contribution of hypertrophic lymph nodes to impaired 
immunity in apoE
-/-
 mice is likely the impaired egress of lymphocytes from the 
lymph node. In addition, intrinsic defects in T cells may also make a minor 
contribution to impaired immunity through their reduced entry into the lymph 
node. Finally, impaired migration of skin DCs to lymph nodes likely further 
contributes to impaired immunity in association with impaired lymphocyte egress 





4.2 The impairment of lymphocyte egress by the microenvironment of the 
hypertrophic lymph node  
 
  
Figure 4.2 The hypertrophic lymph node microenvironment and how it supports impaired 
lymphocyte egress. (i) Hypertrophic lymph nodes may support impaired lymphocyte egress 
through a reduction in the S1P signal, and a disruption of the S1P gradient between lymph and 
blood (ii) Hypertrophic lymph nodes may also support impaired lymphocyte egress through an 
increase in the CCL21 retention signal (iii) Impaired lymphocyte egress may be supported by 
hypertrophic lymph nodes through disrupted lymph flow in lymph node and efferent lymphatic 
vessels (iv) Finally, hypertrophic lymph nodes may also support impaired lymphocyte egress 
through dysfunctional lymphatic vessels within the organ.   
 
Our mass spectrometry measurement of S1P levels in the lymph node, efferent 
lymph and blood of WT and apoE
-/-
 mice suggests that the lymph node 
microenvironment supports impaired lymphocyte egress in part, through a 
reduction in S1P levels inside the efferent lymph and lymph node. This is because 
reduced S1P levels likely result in a decrease in S1P interaction with its receptor 
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S1P1 on lymphocyte surfaces, and this weaker S1P signal subsequently reduces 
the ability of the lymphocyte to overcome the CCL21 retention signal (Pham et 
al., 2008) thereby resulting in impaired egress (Figure 4.2i).  
In addition, the S1P concentration gradient between the lymph node, lymph as 
well as blood is essential for lymphocyte egress (Schwab et al., 2005), and our 
mass spectrometry results demonstrated that there was a significant difference in 
S1P levels within apoE
-/-
 efferent lymph and blood as compared to WT mice. This 
suggests that the S1P concentration gradient between the lymph and blood may 
also be disrupted in apoE
-/-
 mice, and this disruption may further contribute to 
impaired lymphocyte egress in the mouse. Therefore, the lymph node 
microenvironment supports impaired lymphocyte through a possible disruption of 
the S1P concentration gradient (Figure 4.2i). 
The CCL21 immunofluorescence microscopy and ELISA results suggest that 
the hypertrophic lymph node microenvironment may also support impaired 
lymphocyte egress through an increase in the CCL21 retention signal especially at 
the cortical sinuses. This is because CCL21 blocks lymphocyte entry into the 
cortical sinus in the 1
st
 step of lymphocyte egress from the lymph node by 
retaining the cell within the stroma (Pappu et al., 2007). Thus, the increased 
CCL21 retention signal in lymph nodes of apoE
-/-
 mice reduces the probability 
that an egressing lymphocyte can overcome it, and this prevents the cell from 
entering the cortical sinus and leaving the lymph node (Figure 4.2ii).  
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Our lymphangiography results demonstrated that Evans Blue dye was not 
contained within the apoE
-/-
 efferent lymphatic vessel but leaked out into the 
surrounding tissue instead. This leakage may be due to impaired lymphatic 
transport of the dye and impaired lymphatic transport may occur as a result of 
reduced pumping activity in the efferent lymphatic vessel (Lim et al., 2009). 
Therefore, lymph flow might be disrupted in efferent lymphatic vessels of apoE
-/-
 
mice. Further support for the presence of disrupted lymph flow may be seen in the 
enlarged regions along efferent lymphatic vessels of apoE
-/-
 mice. These enlarged 
regions were likely caused by lymph accumulation within the vessel, and may be 
mediated by dysfunctional valves inside the vessel which resulted in a backflow 
of lymph and its accumulation (Lim et al., 2009). Therefore, our 
lymphangiography results showed that apoE
-/-
 mice exhibit dysfunctional efferent 
lymphatic vessels as well as disrupted lymph flow in these vessels. 
Because a disruption in lymph flow at the downstream efferent lymphatic 
vessels may also disrupt lymph flow in upstream lymphatic vessels of the lymph 
node, and lymph flow is essential for the transport of lymphocytes to the medulla 
during egress (Grigorova et al., 2009), our lymphangiography results suggest that 
the hypertrophic lymph node microenvironment also supports impaired 
lymphocyte egress in part through a disruption in lymph flow within lymph node 
and efferent lymphatic vessels (Figure 4.2iii).   
Previous studies have demonstrated that remodeling of cortical and medullary 
sinuses supports lymphocyte egress from the lymph node during late 
inflammation (Tan et al., 2012). However, although our flow cytometry and 
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immunofluorescence microscopy results demonstrate that although remodeling of 
the cortical and medullary lymphatic vessels and an expansion of the lymphatic 
vessel network also did occur in hypertrophic lymph nodes of apoE
-/-
 mice, this 
remodeling was associated with reduced lymphocyte egress from the organ 
instead of restoring it. Therefore, these results suggest that lymphatic vessels in 
hypertrophic lymph nodes of apoE
-/-
 mice were likely to be dysfunctional. Thus, 
the hypertrophic lymph node microenvironment also supports impaired 
lymphocyte egress through dysfunctional lymphatic vessels in the lymph node 
(Figure 4.2iv).  
In conclusion, the hypertrophic lymph node microenvironment likely supports 
impaired lymphocyte egress through 4 different mechanisms namely: i. reduced 
S1P levels and a disrupted S1P concentration gradient, ii. increased CCL21 
retention signal, iii. disrupted lymph flow in lymph node and efferent lymphatic 
vessels and iv. dysfunctional lymphatic vessels in the lymph node. Finally, it is 
also possible that these 4 mechanisms work together to impair lymphocyte egress. 
 
4.3 The lymph node microenvironment exerts a huge influence on cellular 
egress and is a desirable target for the therapeutic blockade of cellular 
egress from the lymph node  
Our long term adoptive transfer of WT donor cells which possess no defects 
in their egress apparatus into the apoE
-/-
 lymph node microenvironment, and 
subsequent impaired egress of the WT donor cells demonstrated that, the lymph 
node microenvironment exerts a huge influence on egress from the lymph node. 
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This is because the hypercholesterolemic apoE
-/-
 lymph node microenvironment is 
able to impair cellular egress even though the donor cells were WT.  
The lymph node microenvironment likely exerts a huge influence through its 
provision of the necessary ‘infrastructure’ for cellular egress such as S1P 
signaling, S1P concentration gradient, functional lymphatic vessels etc. Our S1P, 
CCL21 and lymphangiography results demonstrate that all these pathways are 
involved in egress. Therefore, when the cellular egress ‘infrastructure’ of the 
lymph node microenvironment became abnormal within hypertrophic lymph 
nodes of apoE
-/-
 mice, impaired cellular egress from the lymph node occurs.  
Having shown the substantial involvement of the lymph node 
microenvironment in cellular egress, we would like to suggest that the lymph 
node microenvironment is also a desirable target for the therapeutic blockade of 
cellular egress in the treatment of autoimmune disease. This is because although 
different leukocytes may possess different egress mechanisms, these cells likely 
share common egress routes such as the lymphatic vessels. Therefore, targeting 
the egress components of the lymph node microenvironment such as lymphatic 
vessels may allow us to block a larger variety of leukocyte subsets, and achieve a 
wider immunosuppressive effect (Figure 4.3).  
In conclusion, our long term adoptive transfer of WT donor cells into apoE
-/-
 
recipients demonstrated the huge influence of the lymph node microenvironment 
in cellular egress from the lymph node, and suggests that blocking egress through 
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the lymph node microenvironment is a desirable therapeutic strategy because it 
potentially allows a wider immunosuppressive effect. 
 
 
Figure 4.3 Blocking egress by targeting egress components of the lymph node 
microenvironment achieves a wider immunosuppressive effect. Leukocyte A and B enters the 
lymphatic vessel for lymph node egress via different egress mechanisms. Hence, by targeting the 
lymphatic vessels for egress blockade, it is possible to block both leukocyte subsets from egress 




 mouse is a suitable animal model to study the relationship 
between lymphatic vessels and cellular egress from the lymph node  
Our experimental results from mass spectrometry measurements of S1P, 
measurement of CCL21 levels via immunofluorescence microscopy as well as 
ELISA and lymphangiography studies have demonstrated that the hypertrophic 
lymph node microenvironment impaired lymphocyte egress through, the 
alteration of currently known requirements for successful lymphocyte egress 





Figure 4.4 The hypertrophic lymph node and its impairment of lymphocyte egress through 
interfering with egress requirements. The left column describes the egress requirements while 
the right column describes how the lymph node microenvironment interferes with each 
requirement.  
 
The requirement for S1P signaling in egress (Matloubian et al., 2004) was 
affected by the hypertrophic lymph node microenvironment through reduced S1P 
levels in efferent lymph as well as lymph nodes, and a possible disruption of the 
S1P concentration gradient at the efferent lymph and plasma compartments 
(Cyster and Schwab, 2012; Pappu et al., 2007; Pham et al., 2010; Schwab et al., 
2005). In addition, hypertrophic lymph nodes showed increased CCL21 levels 
particularly at the cortical sinuses which, when combined with lowered S1P levels 
in lymph node and efferent lymph, likely alters the requirement of S1P dominance 
over CCL21 for entry into the cortical sinus (Pham et al., 2008). Last of all, 
lymphangiography studies suggest the presence of disrupted lymphatic flow and 
transport out of the lymph node, and this likely interferes with the requirement for 
flow within lymphatic vessels to transport egressing lymphocytes from the 
cortical sinus to, the medulla and out of the lymph node (Cyster and Schwab, 
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2012; Grigorova et al., 2009). Therefore, these results suggest that the apoE
-/-
 




 mice also display other systemic defects beyond lymph node 
hypertrophy, and impaired lymphocyte egress. Previous studies have 
demonstrated that apoE
-/-
 mice exhibit dysfunctional initial and collecting 
lymphatic vessels in association with hypercholesterolemia (Lim et al., 2009). In 
this present study, we have shown in Section 4.2 that dysfunctional efferent 
lymphatic vessels were present in apoE
-/-
 mice, and also suggested that lymphatic 
vessels in hypertrophic lymph nodes were likely dysfunctional because 
remodeling of the lymphatic vessels was associated with reduced lymphocyte 
egress instead of restored egress (Tan et al., 2012). Therefore, impaired 
lymphocyte egress from hypertrophic lymph nodes of apoE
-/-
 mice likely occurred 
in association with dysfunctional lymph node lymphatic vessels.  
Finally, because Ezetimibe treatment in apoE
-/-
 mice resulted in the 
amelioration of lymph node hypertrophy through remodeling of dysfunctional 
lymphatic vessels within the lymph node, and occurred in association with a 
reduction in plasma cholesterol levels, we suggest that the apoE
-/-
 mice is thus a 
suitable experimental animal model to investigate the relationships between 
hypercholesterolemia, lymphatic vessel dysfunction and cellular egress from the 





4.5 Future work  
Our short term adoptive transfer results demonstrated that the hypertrophic 
lymph node microenvironment likely mediated increased lymph node B cell 
counts by also supporting increased B cell entry into the lymph node. Therefore, 
we seek to understand how the lymph node microenvironment supports increased 
B cell entry, and will address this question by looking at CXCL13 levels at an 
overall organ level, and in the HEVs through ELISA and immunofluorescence 
microscopy. This is because CXCL13 is involved in B cell entry into the lymph 
node via HEVs (Okada et al., 2002) but not T cells and thus, higher CXCL13 
levels in the hypertrophic lymph nodes or at the HEVs may support increased 
recruitment of B cells.  
Because Ezetimibe treatment in apoE
-/-
 mice likely reduced lymph node B cell 
counts by other mechanisms beyond B cell egress, we wondered whether the 
reduction in B cell count during Ezetimibe treatment was due to reduced entry of 
B cells into the lymph nodes instead. Hence, further short term adoptive transfer 
assays will also be done to test whether Ezetimibe treatment in apoE
-/-
 mice 
reduces B cell entry into the lymph node, and whether reduced B cell entry was 
supported by changes in the lymph node microenvironment such as reduced 
CXCL13 expression levels in the lymph node.  
We also seek to determine how increased CCL21 expression levels arise at the 
cortical sinus of hypertrophic lymph nodes. Because both FRCs (Link et al., 2007; 
Luther et al., 2000) as well as LECs (Kriehuber et al., 2001) can express CCL21 
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and thus, mediate increased CCL21 expression level on the cortical sinus, we will 
address this question by first doing immunofluorescence microscopy to study the 
localization of the CCL21 layer with respect to the FRCs and LECs for 
preliminary identification of the CCL21 stroma cell source, and subsequently 
confirm the finding by isolating the stroma cell of interest through flow cytometry 
(Tan et al., 2012), and measuring CCL21 mRNA levels by Real-time PCR.  
Finally, we wonder whether the restoration of S1P levels in the efferent lymph 
and lymph nodes of apoE
-/-
 mice can restore lymphocyte egress from the organ, 
and this will be addressed through an induction in LEC overexpression of Sphk 1 
and 2. This is because S1P levels were reduced in the lymph node and efferent 
lymph, both Sphk 1 and 2 catalyzes the synthesis of S1P in vivo (Spiegel and 
Milstien, 2011) and LEC Sphk activity has been shown to be required for 
lymphocyte egress from the lymph node and lymphatic patterning (Pham et al., 
2010).  
Therefore, future studies will seek to address the B cells of hypertrophic 
lymph nodes, and further understand the processes inside the hypertrophic lymph 
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Appendix A – Buffers and Media 
1X PBS 
8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 1000ml H2O, 
pH 7.4 
 
MACS buffer (working concentration) 
0.5% BSA, 2mM EDTA, 1000ml 1X PBS 
pH 7.4 
 
Red blood cell lysis buffer 
0.15M NH4Cl, 10mM KHCO3, 0.1mM EDTA in H2O 
pH 7.4 
 
ELISA wash (PBS-Tween 20) 
0.05% Tween-20 in 1X PBS 
 
Complete DMEM culture media 
DMEM high glucose (4.2g/litre), 10% FCS, 200mM L-Glutamine, 1X Hybridoma 
Fusion and Cloning Supplement (Roche) 
 
Complete RPMI 1640 culture media 
RPMI-1640 high glucose (4.2g/litre), 10% FCS, 200mM L-Glutamine 
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Appendix B – Figures 
Figure 5.1 Representative experiment demonstrating that hypertrophic 
lymph nodes in 22-28 weeks old apoE
-/-
 mice develop in association with the 
progression of atherosclerosis disease. (A) No significant difference (p=0.6443) 
was observed in lymph node cellularity between 6 weeks old WT (2510667 ± 
384805 cells, n=3) and apoE
-/-
 mice (2189667 ± 516306 cells, n=3). (B) However, 
at 22-28 weeks of age (where atherosclerosis is well established), lymph node 
cellularity was significantly increased (*p=0.0022) in apoE
-/-
 mice (5530215 ± 
548578 cells, n=4) as compared to WT mice (1506667 cells ± 294680, n=3).    
 
Figure 5.2 Representative experiment demonstrating that T and B cells are 
significantly increased in hypertrophic lymph nodes of apoE
-/-
 mice. (A) T 
cells were significantly increased (*p=0.0003) in hypertrophic lymph nodes of 
apoE
-/-
 mice (2159291 ± 11236, n=4) as compared to WT mice (852882 ± 
171520, n=3). (B) Similar to the T cells, B cells were also significantly increased 
(*p=0.0095) in hypertrophic lymph nodes of apoE
-/-
 mice (2754138 ± 452952, 







Figure 5.3 Representative experiment demonstrating that both CD4 and CD8 
T cells are significantly increased in hypertrophic lymph nodes of apoE
-/-
 
mice. (A) CD4 T cells were significantly increased (*p=0.0008) in hypertrophic 
lymph nodes of apoE
-/-
 mice (1073190 ± 35917, n=4) as compared to WT mice 
(418017 ± 96623, n=3). (B) CD8 T cells were also significantly increased 
(*p=0.0003) in hypertrophic lymph nodes of apoE
-/-
 mice (1063541 ± 32785, n=4) 












Figure 5.4 Representative experiment demonstrating that Ezetimibe 
treatment in apoE
-/-
 mice ameliorates lymph node hypertrophy. (A) Lymph 
node cellularity was significantly increased (*p=0.0020 and 0.0036 respectively) 
in non-treated apoE
-/-
 mice (9430000 ± 1174000, n=4) as compared to WT 
(2446000 ± 659800, n=4) and Ezetimibe-treated apoE
-/-
 mice (3743000 ± 373300, 
n=4). Finally, lymph node cellularity was not significantly different (p=0.1381) 
between WT (2446000 ± 659800, n=4) and Ezetimibe-treated apoE
-/-
 mice 
(3743000 ± 373300, n=4). (B) T cells were also significantly increased 
(*p=0.0096 and 0.0177 respectively) in non-treated apoE
-/-
 mice (3679000 ± 
607900, n=4) as compared to WT (1067000 ± 341600, n=4) and Ezetimibe-
treated apoE
-/-
 mice (1679000 ± 110100, n=4) but, was not significantly different 
(p=0.1390) between Ezetimibe-treated apoE
-/-
 (1679000 ± 110100, n=4) and WT 
mice (1067000 ± 341600, n=4). (C) Finally, B cells were significantly increased 
(*p=0.0024 and 0.0036 respectively) in hypertrophic lymph nodes of non-treated 
apoE
-/-
 mice (3648000 ± 433300, n=4) as compared to WT (1044000 ± 287500, 
n=4) and Ezetimibe-treated apoE
-/-
 mice (1430000 ± 208100, n=4), and were not 
significantly different (p=0.3178) between Ezetimibe-treated apoE
-/-
 (1430000 ± 
208100, n=4) and WT mice (1044000 ± 287500, n=4). 
